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THE ROLE OF PARP-1 IN THE CELLULAR RESPONSE TO
LOW DOSE RADIATION Anthony Chalmers*, Mick Woodcock,
Peter Johnston. Gray Cancer Institute, Northwood UK
   Introduction: The spectrum of DNA lesions induced by ionising 
radiation varies according to the dose delivered; hence the relative 
importance of different DNA repair proteins is also likely to vary with 
dose. Depletion or inhibition of poly(ADP-ribose) polymerase-1 (PARP-
1) is associated with radiosensitisation to doses of 2 Gy and above; that it 
is activated by single strand breaks and interacts with the base excision 
repair pathway also indicates a potential role in the response to lower 
doses. Inhibition of PARP-1 may thus enhance the response of tumours to 
low dose per fraction and low dose rate radiotherapy protocols. We tested 
the effect of chemical inhibitors of PARP-1 on low dose clonogenic 
survival in a range of hamster fibroblast and human tumour cell lines and 
compared these survival curves with those derived from PARP-1 
knockout mouse embryo fibroblasts (MEF).
 Methods: Clonogenic survival of T98G and U373 human glioma cells, 
V79 and CHO hamster fibroblasts, and 3T3 MEF PARP-1 knockout and 
control cells following low-dose irradiation in the presence and absence 
of chemical PARP inhibitors was measured using a fluorescence-
activated cell sorting assay. Results:  Whilst PARP inhibition induced 
radiosensitisation of V79, CHO and T98G cells in the 0.05 – 0.5 Gy dose 
range, there was no such effect in the PARP-1 knockout cells compared 
with controls.Radiosensitisation to doses greater than 1.5 Gy occurred in 
all cell lines. Discussion: The discrepancy between the effect of chemical 
inhibition of PARP-1 and deletion of the PARP-1 gene may be explained 
by upregulation of compensatory low dose repair mechanisms in PARP-1 
knockout cells. Another possibility is that inhibition of both PARP-1 and 
PARP-2 is required for low dose radiosensitisation. 
UTILISATION OF MICRO AND MINISATELLITE SEQUENCES FOR
INVESTIGATION OF RADIATION INDUCED MUTAGENESIS IN
SOMATIC CELLS 
Marie Boyd, *Anne Livingstone, Kate Hughes, Lesley Wilson, Anne Marie
Clark, Nazia Baig, Susan Ross and Robert J Mairs. 
*Department of Radiation Oncology and Targeted Therapy, CRUK Beatson
Laboratories, Garscube Estate, Glasgow, G61 1BD. 
Characterisation of the mutations induced by  radiation is required in order to
define human tumours which have a radiation specific origin, to improve
radiation protection and to identify patients whose normal tissues are
abnormally prone to radiation damage.  We have devised a sensitive
methodology which allows characterisation of low dose radiation induced
mutations in repeat sequences of human somatic cells in culture .We
analysed micro- and minisatellite sequences of DNA from clones derived
from single irradiated human glioma cells in culture and established a dose
response relationship for mutation induction after irradiation with 1-3 Gy.  
This methodology was applied to investigate  mutagenesis elicited by very
low dose radiation (< 1Gy) whose effects are of importance to both cancer
radiotherapy and radiation protection, in the UVW cell line which displayed
Hyper Radiation Sensitivity (HRS). mini- and microsatellite analysis
demonstrated an increased radiation induced mutation rate at radiation
exposure doses less than 1Gy. Further, both satellite loci show an 8X
increase in radiation induced mutations at 0.3Gy compared to 1Gy.  This
indicated that enhanced radiation induced mutagenesis accompanied
enhanced cell kill at radiation doses below 1Gy. These studies indicate that
low dose γ  -irradiation may have implications for radiation protection and
have far reaching implications for the scheduling of fractionated
radiotherapy, currently employed in cancer treatment.  
LOW DOSE HYPER-RADIOSENSITIVITY IN VIVO 
Jackie Harney
*, Nihal Shah, Susan Short, Michael Joiner, Michelle 
Saunders. MCRW, Mount Vernon Hospital, UK. 
Introduction The laboratory phenomenon of “low dose hyper-
radiosensitivity” (LDHRS) describes an excess of cell kill at doses < 
1Gy relative to that predicted by the LQ model. These biological data
have stimulated investigation into the existence of LDHRS in vivo. 
Methods Following ethical approval, 2 studies were initiated. Skin was 
used as a model of normal human tissue. Study 1: 24 patients receiving 
pelvic radiotherapy (RT) were assessed. Once daily doses of ~0.5Gy and 
>1.0Gy were compared. Biopsies were taken before & during RT & 
analysed to assess the changes in basal cell density (BCD). Study 2: 8 
patients with metastatic tumour nodules to skin were evaluated (40
nodules). The nodules were randomised to receive conventionally
fractionated RT (1.5Gy/day), or ultrafractionated RT (0.5Gy TDS).  Both 
groups were treated for 12 days (18Gy). Measurements were made on
days 0,5,8,12,26 & monthly until regrowth. Biopsies of surrounding skin 
were also taken to assess changes in BCD & proliferation. Results: 
1:Skin (Study 1): 19 patients demonstrate a reduction in BCD in the
low-dose side compared to the high-dose side when BCD is plotted
against dose (significant in 14).  Analysis of the whole data set 
demonstrates a significant reduction in basal cell density in the low dose 
group. If, however, BCD is plotted against time there is a significant 
reduction in BCD in the higher dose group. Study 2: When BCD is 
plotted against time, 7/8 patients demonstrate a greater reduction in BCD
in favour of the conventional RT arm. A significant reverse fractionation 
effect was seen in only 1/8 patients. Proliferative response was similar in 
all patients irrespective of regime. 2: Tumour Nodules: To date 30
paired nodules have regrown.  Analysis of the "radio-resistant" tumours - 
melanoma & sarcoma -demonstrates significant growth delay in favour
of the "ultrafractionated" regime (p = 0.002). Conclusions: There is no
evidence of LDHRS in normal human skin when regimes of equal dose 
intensity are compared. LDHRS occurs in "radioresistant" tumours. 
PREDICTING THE RESPONSE TO RADIOTHERAPY IN EARLY
ONSET BREAST CANCER. 
Stewart G Martin*, Rebecca Salmon, Clare Orridge and David AL 
Morgan.  University of Nottingham, Department of Clinical Oncology, 
City Hospital, Nottingham NG5 1PB 
Approximately 1 in 5 female cancers in the UK are breast cancers
with ~20% occurring in pre-menopausal women. Young age, <40 years
old, is an adverse prognostic factor, notably for local recurrence after
breast conserving treatment.  Treatment options include surgery and
radiotherapy (R/T) to control local disease, and prevent recurrence, and
systemic therapies to combat frank or occult metastatic disease.  Recent
evidence suggests that angiogenesis, as assessed by microvessel density
(MVD), may be an independent prognostic factor in breast carcinoma
but little is known regarding the prognostic significance of either angio-
or lymphangiogenesis in the response of breast cancer patients to post-
operative R/T. 
A retrospective immunohistological study of biopsies from 82
women with early onset breast cancer (ie age <40 at diagnosis) that
underwent breast-conserving surgery and post-operative R/T was
undertaken to investigate the role, and prognostic significance, of
growth factors (GF’s) involved in regulating tumour angio- and
lymphangiogenesis (VEGF and VEGF-D respectively).  Tumour tissue,
and accompanying stroma, were stained using monoclonal antibodies
against the GF’s and against CD34, to assess MVD. Results, obtained
via image analysis, were compared against local recurrence (ie within
the treated breast) free survival (RFS), overall survival (OS) and other
conventional pathological criteria (tumour stage, grade and vascular
invasion). 
Of the three markers only VEGF-D was significantly
associated with both OS (p=0.01) and RFS (p=0.03).  Cox 
multivariate analysis demonstrates that VEGF-D expression was
more significant than conventional criteria indicating the 
importance of this GF for future studies. 
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EVALUATION OF HYPOXIA WITHIN HUMAN PROSTATE
CARCINOMA USING QUANTIFIED BOLD MRI AND
PIMONIDAZOLE IMMUNOHISTOCHEMICAL MAPPING 
Dawn Carnell
*, Rowena Smith, Jane Taylor, James Stirling, Peter
Hoskin, Anwar Padhani. Marie Curie Research Wing,Mount Vernon
Hospital, Northwood, Middlesex, UK. 
 Introduction: The spatial distribution of MRI parameters (R2* & relative 
blood volume rBV) compared to pimonidazole (an extrinsic marker of 
hypoxia) stained tissue sections was used to assess the ability of MRI to 
predict clinically significant prostate cancer hypoxia. This may facilitate 
localisation of an IMRT boost to potentially radioresistant regions of tumour 
in the future.
  Methods: Following local ethical approval, five patients with localised 
prostate carcinoma were imaged with MRI. Multiple gradient echo (TE 5-
75ms) and GRE T2*-weighted images with contrast were used to calculate 
R2* and rBV maps using a gamma variate fit, pixel by pixel, in a single 
plane. Areas of fast R2* equivalent to muscle, and rBV greater than fat, were 
mapped onto a prostate gland outline. 16-24 hours before radical 
prostatectomy 0.5g/m
2 IV pimonidazole was given. Tissue sections in the 
imaging plane were stained to map tumour (H&E) and hypoxia (pimo-
nidazole). Correspondences between MRI metrics with histology were 
performed using 5x5mm grid overlays and a 2x2-table analysis for tumour 
(133 grids) and non-tumour regions (165 grids).
 Results: Hypoxia was seen within carcinoma and benign prostatic 
hyperplasia. In tumour 48/60 grids with fast R2* stained positive for 
pimonidazole and 17/19 with slow R2* stained negative. R2* alone best 
reflected the oxygenation status of tumours, as defined by pimonidazole, 
with a sensitivity of 96% and negative predictive value of 89%.
Conclusion:  R2* best reflected the oxygenation status of tumours 
supporting the hypothesis that unstimulated BOLD-MRI allows non-invasive 
mapping of significant hypoxia within human prostate cancer. This work is 
supported by Cancer Research UK.
GLUT-1 AS A NOVEL TARGET FOR ANTICANCER
THERAPY: A COMPARE ANALYSIS USING THE NCI
PANEL OF 60 CELL LINES 
Andrew Evans,* Stephen Hewitt, Ian J. Stratford, Rachel E. Airley
*School of Pharmacy and Chemistry, Liverpool John Moores
University, Byrom Street, Liverpool, UK
Tumours have an increased rate of glucose uptake relative to benign 
tissue,and tumour hypoxia leads to poor outcome. The increase in glucose 
uptake observed particularly in hypoxic tumours enables a compensatory 
switch to anaerobic glycolysis.This effect is mediated chiefly by the HIF-
1 regulated glucose transporter Glut-1, which predicts poor prognosis in a 
wide variety of solid tumours, including cervix, lung and colorectal 
tumours. Glut-1 is also an intrinsic marker of hypoxia, correlating with 
PO2 and pimonidazole adduct formation. The prognostic effects of Glut-1, 
and their relevance to tumour hypoxia, make Glut-1 an interesting target 
for novel anticancer strategies.  For example, it has been found that 
certain flavonoid tyrosine kinase inhibitors e.g. quercetin, directly bind 
Glut-1, resulting in a sizeable decrease in glucose uptake that may induce 
cytotoxicity. In an effort to find possible lead drugs that may mediate 
their toxicity through Glut-1 binding and inhibition, the level of Glut-1 
expression was investigated in the NCI panel of 60 cell lines, using 
immunohistochemical staining of microarrays containing samples of each 
tumour cell line.  There was a wide variation of Glut-1staining (scored 0-
5 according to staining intensity) between cell lines of the panel.  Data is 
currently undergoing analysis, where any correlation between Glut-1 
score and cytotoxicity of NCI compounds will be highlighted and 
investigated further. This work represents a departure from the traditional 
use of glucose analogues as glycolytic antimetabolites, and instead offers 
an alternative means of exploiting tumour hypoxia by  directly targeting 
and binding to hypoxia-regulated proteins.   
MNG719, A COMBRETASTATIN PRODRUG TARGETED AT 
TUMOUR HYPOXIA, MA Naylor
1, MRL Stratford
1, KB Patel
1, SM
Galbraith
1, SW Doughty
2, RM Phillips
3, and SA Everett
1*, 
1Gray
Cancer Institute, Mount Vernon Hosp, Northwood, Middlx HA6 2JR. 
2The Pharmacy School, Univ Nottingham, Nottingham, NG7 2RD. 
3Cancer Research Unit, Univ Bradford, Bradford, BD7 1DP. 
MNG719, is an indolequinone-based prodrug designed to undergo 
reductive fragmentation in hypoxia to liberate the anti-vascular agent
combretastatin. The impact of MNG719 versus ‘free’ combretastatin 
on human umbilical vein endothelial cell (HUVEC) morphology and 
cytotoxicity were assessed. Target tubulin polymerisation was 
evaluated by a commercially available assay kit. Substrate specificity
and inhibition of recombinant human DT-diaphorase was 
investigated and results interpreted by parallel molecular modelling. 
Metabolic studies were performed with HUVEC cell lysates and 
supersomal cytochrome P450 reductase. Proliferating endothelial cell
area is unaffected by MNG719 in air exposed to doses of the prodrug 
up to 10 µmol dm
-3 for 30 min whereas under anoxia cell shape 
reduction or ‘shrinkage’ is equivalent to doses of combretastatin of 
less than 1  µmol dm
-3. Combretastatin completely inhibits tubulin 
polymerisation at 0.5 µmol dm
-3 but the prodrug is inactive even at a
40-fold higher concentration. Reductive metabolism of MNG719 by
HUVEC cells and cytochrome P450 reductase under anoxia liberates 
combretastatin which is inhibited by air and is reflected in the 
comparative anoxia versus air cytotoxicities. Despite the ‘bulkiness’ 
of MNG719 the prodrug can dock in the active site of DT-diaphorase 
where reductive fragmentation results in enzyme inhibition. The 
results are consistent with MNG719 ‘redox-cycling’ in air but
undergoing reductive fragmentation under anoxia, mainly by
cytochrome P450 reductase, to release combretastatin. Prodrug-
activation is ‘oxygen-sensitive’ and future work will seek to modify
the rate of reductive fragmentation to control hypoxia-selective drug 
delivery. This work is supported by Cancer Research UK
IDENTIFICATION OF TUMOUR  SUPPRESSOR GENES IN
CHILDHOOD MEDULLOBLASTOMA BY PROMOTER
HYPERMETHYLATION PROFILING
Janet C. Lindsey, Meryl E. Lusher, Andrew D.J. Pearson, David
W. Ellison and Steven C. Clifford.
Northern Institute for Cancer Research, University of Newcastle,
Newcastle upon Tyne, UK. 
Medulloblastoma (MB) is the most common malignant brain
tumour of childhood, however the molecular pathogenesis of the
majority of MBs is not understood.  The epigenetic silencing of
tumour suppressor gene (TSG) expression by promoter hyper-
methylation has emerged recently as an important mechanism of
TSG inactivation. To assess the significance of aberrant promoter
methylation events in MB, and to identify critical genes in its
pathogenesis, we profiled the methylation status of eleven
candidate TSGs (p14
ARF, p15
INK4b, p16
INK4a, Caspase 8, HIC-1,
EDNRB, TIMP-3, TP73, TSLC1, RIZ-1 and RASSF1A) in MBs
(11 cell lines, 44 primary tumours) and the normal cerebellum.
Our data show that extensive hypermethylation of the RASSF1A
promoter is a tumour-specific event, which occurs in the majority
(~90%) of MBs. In MB cell lines, RASSF1A methylation was
associated with epigenetic transcriptional silencing.  Moreover,
total RASSF1A methylation was observed in the absence of gene
deletion or mutation, indicating that RASSF1A inactivation in MB
occurs by bi-allelic epigenetic mechanisms. Increased tumour-
specific methylation was also observed for HIC-1 (39%) and
Caspase 8 (32%), in both cases occurring against a background of
normal tissue-specific methylation in the cerebellum. These data
demonstrate that aberrant promoter methylation events are a
significant feature of MB development, and identify putative MB
TSGs. Epigenetic RASSF1A inactivation represents the most
common defect detected to date in MB, emphasising the
importance of its further investigation in this disease. 
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ANTISENSE OLIGONUCLEOTIDE TARGETING OF  
RAF-1:  IMPORTANCE OF mRNA EXPRESSION  
LEVELS IN DETERMINING GROWTH RESPONSE   
Simon P Langdon*
1, Peter Mullen
1, Fiona McPhillips
1, Kenneth  
MacLeod
1, Brett Monia
2 and John F Smyth
1. 
1Cancer Research UK
Edinburgh Oncology Unit, Western General Hospital, Edinburgh  
EH4 2XR ; 
2ISIS Pharmaceuticals, Carlsbad, USA.
     Raf-1 is a member of the Raf serine/threonine kinase family which 
consists of Raf-1 (c-Raf), A-Raf and B-Raf. It is a key intermediate in the 
Ras/Raf/MEK/ERK pathway which relays extracellar signals to the 
nucleus. Over 90% of ovarian carcinomas express Raf-1 protein, with  
high levels correlating with poor survival (McPhillips et al, Br J Cancer, 
85, 1753,2001). In this study we have used a series of 15 ovarian cancer 
cell lines to help identify determinants of sensitivity to anti-Raf-1 
antisense oliogonucleotides (ASOs). Growth inhibition (at 72h) varied 
from 100% down to 12% across this series of cell lines after treatment 
(200 nM for 3h) with either fully phosphorothioated ASO, ISIS 5132,  
(TCCCGCCTGTGACATGCATT) or a further (2’methoxyethyl) 
modified ASO, ISIS 13650. The degree of growth inhibition was not 
associated with level of Raf-1 protein expression, intracellular uptake of 
ASO or extent of Raf-1 protein inhibition after ASO treatment (61-99% 
inhibition). However, growth inhibition was significantly (p=0.019, 
Mann-Whitney) higher in cell lines with a higher proportion of Raf-1 
mRNA (relative to total Raf mRNA i.e. Raf-1 + A-Raf + B-Raf) 
suggesting that greater utilisation of Raf-1 rather than other Raf isoforms 
was important. Consistent with this, growth inhibition was also 
significantly (p=0.04, Mann-Whitney) higher in cell lines which 
demonstrated greater (>2-fold) Raf-1 kinase activation after growth factor 
(1nM TGF α) stimulation. These results indicate that ovarian cancer cell 
lines demonstrate variable growth sensitivity to anti-Raf ASOs but 
sensitive tumors can feasibly be identified. 
THE BIOLOGICAL ACTIVITY OF ENDOTHELIAL 
HEPARAN SULFATE IN SEROUS ADENOCARCINOMA
OF THE OVARY  
Melissa K. Whitworth
*, Godfrey Wilson, Richard Slade, John
Gallagher, Alan Rapraeger and Gordon Jayson. Cancer Research
UK Department of Medical Oncology, Christie Hospital NHS
Trust, Wilmslow Road, Manchester, M20 4BX, UK. 
  Fibroblast growth factor-2 (FGF2) is a potent angiogenic factor, which 
requires heparan sulfate proteoglycans (HSPGs) for its biological 
activity. HSPGs mediate stable high affinity binding of FGF2 to its 
receptor tyrosine kinases (FR). The aim of this study was to investigate 
the biological activity of epithelial ovarian cancer (EOC) endothelial HS 
with respect to the activation of FGF2.
  We examined the ability of HSPGs to promote FGF2/FR binding using 
a soluble FR fusion construct (FR1-AP) (1). This encodes the 
extracellular domain of FR1 linked to alkaline phosphatase (AP). In 
addition we developed IHC techniques to assess the expression of 
endogenous FGF2, FR1 and FR2 and a doublestain technique to assess 
HS chain expression on ECs.
 FGF2 binding was HS chain dependent. HSPGs capable of supporting 
FGF2 binding are present on ECs and throughout the stroma and 
epithelium. FGF2/FR1-AP fusion complex localisation is significantly 
different from FGF2 localisation (p<0.0005), suggesting that HS chains 
held in an active configuration are located primarily on ECs. FR1 and 
FR2 have a variable distribution within EOC specimens and are found 
mainly on stromal and epithelial cells. The double stain technique 
confirms that HS chains are present on ECs.
  We have shown for the first time that the HS expressed by ECs in EOC 
has the capacity to activate FGF2, an angiogenic protein. This identifies 
HS as a potential target for anti-angiogenic therapies. (1) Chang et al. 
(2000) Faseb J. 14, 137 
DYSREGULATION OF CELL CYCLE CONTROL PROTEINS 
DURING CERVICAL GLANDULAR CARCINOGENESIS
Alaa A. El-Ghobashy*
1, Abeer M. Shaaban 
1, Jonathan Herod 
2, 
Jenny Innes 
1, Wendy Prime, Simon Herrington 
1
1Department of Cellular and Molecular Pathology, the University
of Liverpool and 
2Liverpool Women’s Hospital, Liverpool, UK 
   A putative pathway for cervical glandular carcinogenesis exists 
from normal glands through cervical glandular intraepithelial 
neoplasia (CGIN) to invasive adenocarcinoma. Cyclins and 
CDK-inhibitors are known to play a crucial role in regulating cell 
cycle. We aimed to identify biological markers that define early
cervical glandular neoplasia and to differentiate CGIN from their 
benign mimics. Paraffin-embedded sections of normal cervix 
(Group: 1, n=11) edometriosis/TEM (Group: 2, n=19), CGIN 
(Group: 3, n=33) and invasive adenocarcinoma (Group: 4, n= 28) 
were stained with p16, cyclins A, B, D and E. A high level of 
p16 expression was found in CGIN (mean: 81.4%)  and invasive 
adenocarcinoma (84.4%)  when compared with normal endocervix 
(2.3%). Levels of cyclin A, cyclin B and p16 in CGIN were 
significantly higher than those in group 2 (P= 0.05, <0.001 and 
<0.001 respectively). A progressive increase in cyclin A and B 
expression occurred from normal cervix to invasive 
adenocarcinoma. The latter expressed higher levels of cyclin A 
and B when compared with CGIN (P<0.001). Cyclin E 
expression increased from group 1 to 2 (P=0.03) with no 
significant further increase. Changes in Cyclin D expression 
were unremarkable. Our data highlight that p16 could be used as 
a marker for cervical glandular neoplasia. Concurrent expression 
of cyclin A, cyclin B and p16 can help distinguish between 
CGIN and TEM/endometriosis.  
ASSOCIATION OF VITAMIN D RECEPTOR GENE
POLYMORPHISMS WITH BREAST CANCER RISK AND
PROGRESSION. 
Michelle Guy*, Lorraine C. Lowe, Janine L. Mansi, Rosalind
Given-Wilson, Valerie Thomas and Kay W. Colston.  
St George’s Hospital Medical School, London, SW17 0RE, UK.
   Aims: The steroid hormone vitamin D is thought to protect
against breast cancer (BC). Vitamin D exerts its cellular effects by
binding to the vitamin D receptor (VDR). The VDR has several
polymorphic sites, resulting in differing genotypes that may alter
susceptibility to BC. We have investigated whether specific
polymorphisms in the VDR gene are associated with BC risk in a
UK Caucasian population.  
Methods: Female BC patients (n=411), and control women with
a negative screening mammogram (n=427) were recruited, and
their VDR genotypes were determined.  
Results: The 3′   VDR polymorphism BsmI and a variable length
Poly A sequence were both significantly associated with BC risk;
odds ratio bb vs BB genotype = 1.74, (P=0.0096); odds ratio LL vs
SS = 1.70, (P=0.0146). A 5′   VDR gene variant, FokI was not
associated with BC risk when analysed in isolation (P=0.31).
However, FokI modulated the increased risk associated with the
bb/LL genotype such that possession of one or more F alleles
together with the bb/LL genotype augmented the risk of BC.
Furthermore, the highest proportion of bb (53%) and FFLL/FfLL
(52%) genotypes occurred in women with distant metastatic BC,
and 73% of established cell lines derived from BC metastases
(n=15) displayed the bb/LL genotype.
Conclusions: VDR polymorphisms are associated with BC risk
and progression. This research has implications for the monitoring
and treatment of women at risk of BC, and for those likely to
develop metastasic disease. Future research will investigate the
effect of genotype on VDR function. 
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ESTROGEN CAN MODULATE ESTROGEN RECEPTOR-
INDEPENDENT SURVIVAL PATHWAY IN HUMAN BREAST 
CANCER.   Kheng T. Lim*, Arnold D.K. Hill, Enda W. McDermott, 
Niall J. O’Higgins, Leonie S. Young.  Department of Surgery, St. 
Vincent’s University Hospital and the Conway Institute for 
Biomolecular and Biomedical Research, University College Dublin, 
Dublin 4, Ireland. 
 In breast cancer, steroids in particular estrogen, functioning through its 
receptors (ER) contribute to tumour progression by regulating the transcription 
of target genes. Recent studies however suggest that estrogen may also up-
regulate the mitogen-activated protein kinase (MAPK) pathway, mimicking the 
effect of growth factors such as epidermal growth factor (EGF). This clinical 
observation suggests that estrogen may be able to mediate some of cell survival 
properties through an ER-independent mechanism.
 The ER-positive MCF-7 and the ER-negative SKBR3 human breast cancer 
cell lines were incubated in the presence and absence of EGF and estrogen with 
or without G-protein coupled receptor (GPCR) inhibitor, pertussis toxin and 
EGF receptor inhibitor, AG 1478. Phospho-c-raf, phospho-Erk, phospho-cdc2 
and survivin expression were detected using western blotting techniques.
  In MCF-7 and SKBR3 human breast cancer cells, we have found that EGF 
and estrogen stimulation rapidly increased the phosphorylation of c-raf, Erk 
and subsequently an increase in cdc2 phosphorylation and an up-regulation of 
survivin expression. A further increase was noted in the presence of EGF in 
combination of estrogen. Moreover, estrogen induced a translocation of 
phospho-cdc-2 from the cytosol to the nucleus indicating activation of the 
phospho-cdc-2/survivin complex. The effects of EGF on phosphorylation of c-
raf, Erk, cdc2 and survivin were attenuated by AG1478. The effects of 
estrogen on phosphorylation of c-raf, Erk, cdc2 and survivin were attenuated 
by pertussis toxin and to the lesser extent by AG1478.
  These observations implicate estrogen in the MAPK cell survival mechanism 
and survivin anti-apoptotic pathway. Elucidation of ER-independent estrogen 
survival pathways may in part explain clinical observations of steroid therapy 
resistance in breast cancer.  
HER2 OVEREXPRESSION CONFERS RELATIVE
RESISTANCE TO ZOLEDRONIC ACID IN VITRO
Lisa M Pickering*, Jon P Coxon, Janine L Mansi, Kay W Colston 
St. George’s Hospital Medical School, London. UK. SW17 0RE. 
Her2 receptor overexpression confers an increased risk of breast
cancer recurrence and is associated with relative resistance to many
endocrine and chemotherapeutic agents. Bisphosphonates,
particularly potent third generation compounds such as zoledronic
acid (ZA), limit skeletal morbidity in patients with advanced breast
cancer. We have previously shown that ZA induces apoptosis in
her2 non-overexpressing breast cancer cell lines and limits their
capacity to adhere to mineralised matrices. This study aimed to
investigate whether her2 receptor overexpression attenuates
sensitivity to these ZA-induced anti-cancer effects.
Adhesion was assessed by seeding viable cells onto extracellular
matrices for 24 hours. Adherent cells were then washed, fixed,
stained and counted. Induction of apoptosis was assessed by the
cell death ELISA and MTS cell viability assays.  
Forced her2 receptor overexpression in the non-malignant breast
epithelial cell line Hb4a resulted in a 2-fold increase in their
capacity to adhere to mineralised matrix. Treatment with 1nM-
50µM ZA for 24h resulted in a significant reduction in adhesion of
two non-her2 receptor overexpressing cell lines cells, with a
reduction in adhesion of 50-85% in MCF-7 cells and 35-80% in
MDA-MB-231 cells. However the her2 receptor overexpressing
SKBr3 cell line experienced only 16% reduction in adhesion with
ZA treatment. Furthermore, whilst ZA induced apoptosis in all
three cell lines, a significantly lower percentage of SKBr3 cells
than either MCF-7 or MDA-MB-231 cells underwent apoptosis.
      In conclusion, these results support the observation that her2
receptor overexpression is associated with increased metastatic
potential and suggest that it confers relative resistance to ZA. 
SRC-1 EXPRESSION IS ASSOCIATED WITH ENDOCRINE 
RESISTANCE IN BREAST CANCER 
Fergal Fleming*, Arnold Hill, Enda Mc Dermott, Niall O’Higgins, 
Leonie Young
Department of Surgery, St Vincent’s University Hospital and Conway
Institute of Biomolecular and Biomedical Research, University
College Dublin, Ireland 
  ER-α   and ER-β function as transcription factors to modulate genes 
relevant to breast cancer progression.  Both interact with nuclear 
regulatory proteins to enhance or inhibit transcription. Following 
ethical approval ER-α, ER-β, the co-activator SRC-1, and the co-
repressor SMRT were localized within breast tissue by
immunohistochemistry, and their spatial co-expression assessed by
immunofluoresence.  The expression of ER-α, ER-β and the 
coregulators was correlated with clinicopathological features.  The 
ability of β-estradiol and 4-hydroxytamoxifen    (4-OHT) to modulate 
protein expression of ER-α  , ER-β  , SRC-1, and SMRT in primary
breast cancer cell cultures was assessed by immuno-blotting.   SRC-1 
was found to be significantly associated with nodal positivity and 
resistance to endocrine treatment. There was up-regulation in ER-
β and the co-regulator protein expression in the presence of β  -
estradiol. 4-OHT induced an increase in ER-α   and SMRT, whereas it 
decreased or unaltered the protein expression of ER-β   and SRC-1. 
Associations between SRC-1 expression and recurrence suggest that 
co-activators may impact on the clinical phenotype of the tumour. The 
differential regulation of the ER-isoforms and the co-regulators by β  -
estradiol and 4-OHT provides evidence that co-regulatory proteins 
may have a role in determining the response of breast cancer cells to 
estrogen and tamoxifen. 
ABERRANT EXPRESSION OF INTERLEUKIN-7 (IL-7) AND
ITS RECEPTOR (IL-7R) IN BREAST CANCER AND THE 
ASSOCIATION WITH PROGNOSIS. Mahir A A Al-Rawi*, 
Robert E Mansel and Wen G Jiang. Department of Surgery,
University of Wales College of Medicine, Cardiff  CF14 4XN UK
  IL-7 is known to induce the differentiation and proliferation of some 
leukaemias and lymphomas. Although it has been implicated in the 
process of lymphangiogenesis, Little is known about its role in solid 
tumours including breast cancer. We studied the expression of IL-7 and 
its receptor, IL-7R, in a cohort of patients with breast cancer.
  Tumour (n=122) and normal (background) tissues (n=41) from patients 
with breast cancer (median follow up 72.2 months) were analysed for the 
level of mRNA of IL-7 and IL-7R, using quantitative RT-PCR, and 
protein using Western blotting and immunohistochemistry. The results 
were analysed according to tumour grade, nodal involvement, patients 
survival rate and prognosis (using the Nottingham Prognostic Index).
  The expression of IL-7 was higher in the cancer tissues compared to the 
background tissues. IL-7 was significantly higher in grade 3 tumours 
compared to grades 2 and 1 (P=0.03). Ductal carcinomas highly 
expressed IL-7 compared with lobular tumours (P=0.08). Furthermore, 
IL-7 expression was significantly higher in the node positive group 
compared to the node negative patients (P=0.03). Number of copies of 
IL-7 was higher in the worst prognosis group (NPI3) compared to the 
good prognosis group (NPI1) (P=0.004). Additionally, patients who died 
from breast cancer had significantly higher IL-7 expression in their 
tumours compared with the survivals (P=0.03). The expression of IL-7R 
was also significantly elevated in node positive tumours and in patients 
with NPI3.
   This is the first study to show that IL-7 expression is associated with 
tumour grade, nodal involvement and prognosis in breast cancer. 
Aberrant expression of IL-7 and IL7R in breast cancer may be involved 
in the progression and spread of breast cancer. 
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MECHANISMS OF TELOMERASE INHIBITION BY NOVEL 
POLYCYCLIC ACRIDINES
Jennifer C. Cookson*, Robert Heald, Laurence Hurley, Malcolm
F. G. Stevens.  *Cancer Research Laboratories, School of 
Pharmaceutical Sciences, University of Nottingham, UK
A series of novel polycyclic acridines inhibit telomerase in the TRAP assay 
(
telIC50 ~ 0.3µM) and are highly promising potential new anti-cancer agents.  
The lead compound, RHPS4 (4,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-
kl]acridinium methosulfate) exhibits anti-proliferative effects, induction of 
senescence and reduction in telomere length; cell extracts incubated with 
RHPS4 show reduced telomerase activity. Modelling, biophysical and NMR 
data suggest the compounds stabilise G-quadruplex structures such as those 
formed in the telomeres and possibly the c-myc oncogene promoter.
  The c-myc  gene is capable of activating telomerase by increasing 
expression of the catalytic subunit of telomerase (TERT).  We investigated 
whether the polycyclic acridines might stabilise a quadruplex structure in the 
c-myc promoter and reduce cellular expression of c-myc and possibly in turn 
hTERT.  A cell-free, polymerase stop assay revealed potent stabilisation by 
the compounds of a G-quadruplex structure in the c-myc promoter sequence.  
Effects on c-myc  expression in vitro were evaluated by RT-PCR with 
members of the series eliciting a modest reduction in c-myc and hTERT 
mRNAexpression in cancer cell lines. However, the reduction in hTERT 
expression does not appear to be mediated exclusively through a reduction in 
c-myc and the pattern of c-myc down-regulation in cells does not correlate 
with G-quadruplex stabilisation in the stop assay. Thus we conclude that the 
anti-proliferative and telomerase inhibitory effects of these compounds are 
not significantly mediated through a reduction in c-myc expression, but more 
likely through direct interaction with the telomeres. 
IDENTIFICATION OF pVHL-INTERACTING PROTEINS AND
THEIR ROLE IN PHEOCHROMOCYTOMA DEVELOPMENT 
James C. Cooke* and Steven C. Clifford.   
Northern Institute for Cancer Research, The Medical School,
University of Newcastle-upon-Tyne, NE2 4HH, U.K. 
 
   von Hippel-Lindau disease (VHL) is a dominantly inherited familial 
cancer syndrome caused by mutations of the VHL tumour suppressor 
gene (TSG). VHL predisposes to the development of tumours including 
renal cell carcinoma (RCC), hemangioblastoma (HAB) and 
pheochromocytoma (PHE). Distinct patterns of tumour development 
and genotype-phenotype correlations exist in VHL disease, suggesting 
multiple and tissue-specific functions for pVHL, the VHL TSG protein 
product. pVHL plays a critical role in the regulation of hypoxia 
inducible factor-1α (HIF-1α) and cellular oxygen sensing. We recently 
showed that disruption of HIF-1α regulation by disease-associated 
pVHL mutants correlated with RCC and HAB predisposition in VHL 
disease, however HIF-1α de-regulation was not associated with PHE 
susceptibility.
    To investigate further pVHL functions that may play a role in VHL-
associated PHE development, we have performed a yeast-2-hybrid 
screen against a PHE-representative cDNA library to identify putative 
pVHL-interacting proteins. This assay initially identified 100 potential 
pVHL-interacting clones. Twenty of these were characterised in detail, 
and 10 unique binding species were identified which represented in-
frame protein coding sequences.  These included 6 uncharacterised 
cDNAs and 4 known proteins including the zinc finger protein, Zbrk-1, 
and eNOS-interacting protein. The specificities of all ten interactions 
were confirmed in yeast using small-scale yeast-2-hybrid assays.
    The ten pVHL-interacting proteins identified are now the focus of 
further investigations to establish their in vitro and in vivo significance, 
and any role they may play in PHE development. 
THE ANTI-APOPTOTIC MCL-1 PROTEIN PLAYS A KEY
ROLE IN B-LYMPHOMA CELL SURVIVAL  
Jorg Michels *, Eric Marcusson, Peter W.M. Johnson, Graham
Packham, Cancer Research UK, Cancer Sciences Division, 
University of Southampton, Southampton, UK. 
   Introduction: Mcl-1 is an anti-apoptotic Bcl-2 family protein that is 
frequently expressed in malignant lymphocytes. Mcl-1 is often down 
regulated early during apoptosis. Here we have used anti-sense 
techniques to determine the importance of Mcl-1 expression in 
controlling B-cell lymphoma survival.
    Methods: Akata6 cells (B-cell lymphoma cell line) were transfected 
with Mcl-1 antisense or missense oligonucleotides (ODN) using 
electroporation in the presence or absence of ZVAD-fmk. Expression of 
Bcl-2 family proteins (Bcl-2, Bcl-XL, Mcl-1), caspases and PARP was 
determined by immunoblotting.
   Results: Transfection of Mcl-1 antisense, not missense ODN resulted 
in early down regulation of Mcl-1 protein in contrast to related 
molecules, Bcl-2 and Bcl-XL. Down regulation of Mcl-1was followed by 
activation of caspases and cleavage of PARP, a caspase substrate. 
Activation of caspases by the Mcl-1 antisense ODN was accompanied 
by the appearance of a 28kDa Mcl-1cleavage fragment, suggesting that 
Mcl-1 is also cleaved by caspases during apoptosis. The 28 kDaMcl-1 
cleavage product was also detected during cisplatin-induced apoptosis of 
Akata6 cells.  Treatment with ZVAD-fmk prevented caspase activation 
and Mcl-1 cleavage induced by Mcl-1 antisense ODN, but not the initial 
decrease in Mcl-1 protein levels preceding these events.
  Conclusions: These data demonstrate that Mcl-1 is a key survival 
molecule for B lymphoma cells. Down regulation of Mcl-1 by antisense 
ODN is sufficient to activate apoptotic pathways and caspase mediated 
cleavage of Mcl-1 may function as a positive feedback loop to ensure 
efficient cell killing.  
MOLECULAR GENETICS, PATHOLOGY & PHYSIOLOGY OF GLIOMAS
TREATED BY PCV CHEMOTHERAPY  
Carol Walker
+*, Daniel DuPlessis
#, Kathyrn A. Joyce
+, Trevor Smith
#, Sobhan
Vinjamuri
†, Brian Haylock
∞ , David Husband
∞ , Aditya Shenoy
∞ , John Broome
#
and Peter C. Warnke
#+ Clatterbridge Cancer Research Trust and
∞Clatterbridge Centre for Oncology, Clatterbridge Hospital, Bebington, Wirral,
CH63 4JY; 
#Walton Centre for Neurology and Neurosurgery and 
†Royal
Liverpool University Hospital, Liverpool, UK. 
The diagnosis and treatment of oligodendroglial neoplasms is
currently highly controversial. Loss of chromosomes 1p and 19q
may be predictive of chemosensitivity, while tumour physiology
influences drug delivery and therapeutic responsiveness.  
In a prospective study of 65 gliomas treated with PCV
chemotherapy at a single treatment centre, laser capture
microdissection and microsatellite analysis was used to determine
allelic losses. 11/18 OII, 5/18 OAII, 9/10 OIII, 6/18 OAIII and 0/1
GBMO had loss of both 1p36 and 19q13.  3 OII, 7 OAII, 3 OIII, 9
OAIII and 1 GBMO had loss of 17p13 and 5 OIII and 7 OAIII had
losses in chromosome 10.  Inter or intratumoral heterogeneity of
histological subtype seen in 9 cases, was not reflected in genetic
heterogeneity. Comparison of pre-treatment molecular genetics and
physiology data suggests that tumours with 1p36/19q13 loss are
more likely to have increased uptake of 
201Tl. For a subset of cases,
pre and post therapy in vivo imaging data, including 
1H MR
Spectroscopy, rCBV, 
18FDG-PET and 
201 Tl-SPECT is being used
to assess radiological responses. For example, a hypermetabolic
anaplastic tumour with loss of 1p36/19q13 responded completely
to PCV, while a hypermetabolic anaplastic tumour with loss of
17p13 and mutant p53 progressed. Continued clinical follow–up
will elucidate the complex physiological and molecular factors that
may influence chemosensitivity in oligodendroglial neoplasms. 
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MONITORING OF IMMUNOLOGICAL CHANGES AFTER 
ADMINISTRATION OF A WHOLE CELL ALLOGENEIC
PROSTATE CANCER VACCINE. 
Whelan M.A.
*1, Michael A.
2, Quatan N.
2, Russell N.
1, Whelan J.
1, 
Wushishi F.
1 & Pandha H.
2 
1Onyvax Ltd. &
2Dept. of Oncology, St. George’s Hospital Medical
School, Cranmer Terrace, London, SW17 0RE, UK. 
ANTI-CANCER DRUG INTERACTION WITH CYTOCHROME
P450 CYP1B1 
Morag C E McFadyen*, William T Melvin, Graeme I Murray
Department of Pathology, University of Aberdeen, Aberdeen,
AB25 2ZD UK. 
THE TREATMENT OF WILMS’ TUMOUR: RESULTS OF THE UNITED
KINGDOM CHILDREN’S CANCER STUDY GROUP THIRD WILMS’
TUMOUR STUDY.
Christopher Mitchell 
(1)  Rosemary Shannon, Gordan, M Vujanic, Anna
Kelsey,  Peter Gornall   Jenny Walker, Richard Grundy, Catherine Owens,
,
Roger Taylor
(,Kathy Pritchard Jones, John Imeson,
, Helen Middleton, Carolyn
Hutton, 
,Jon Pritchard, For the United Kingdom Children’s Cancer Study
Group. 
1.  Paediatric Oncology, Oxford Radcliffe Hospital, Oxford OX 9DU. 
  Background:  The prognosis for children with Wilms tumour has improved 
steadily over the past four decades so that it is now possible to focus on 
treatment refinement with a view to reduction of short and long-term side effects.  
One remaining area of contention is the timing of surgical resection.  It has been 
suggested that the use of preoperative chemotherapy might reduce the risks of 
surgical intervention and might, by identifying tumours that are chemosensitive, 
reduce the total burden of therapy needed by patients fortunate enough to have a 
responsive tumour.
   Methods:  Children with nonmetastatic renal tumours that were judged to be 
surgically resectable were randomly assigned either to immediate nephrectomy 
or to percutaneous biopsy followed by six weeks of chemotherapy with 
actinomycin D and vincristine followed by delayed nephrectomy.  In both arms 
postoperative therapy was dictated by the tumour stage assigned at the time of 
nephrectomy.
  Results:  During the period October 1991 to March 2001) of the 607 eligible 
patients, 205 were randomised.  Of this group 21 were subsequently found to 
have non-Wilms histology. There were 94 patients who had immediate 
nephrectomy and 90 patients who had preoperative chemotherapy.  Analysis of 
the stage distribution in the two arms shows a highly significant improvement in 
the stage distribution for the preoperatively treated group (stage I: 66.3 vs 55.3, 
stage II: 23.3 vs 14.9, stage III: 10 vs 29.8%).  EFS and OS were equivalent 
between the two arms.  There was also a reduction in peroperative tumour 
rupture and other surgical complications.
  Conclusions:  Six weeks of preoperative therapy with vincristine and 
actinomycin D for patients with Wilms tumour identifies patients with 
chemoresponsive tumours and leads to a more favourable stage distribution, 
permitting a reduction in the overall burden of their therapy without 
compromising the chances of cure.  
 Allogeneic whole cell vaccines are a practical approach to 
immunotherapy. They do, however, present unique challenges for 
clinical trial monitoring since their multivalent antigenic nature makes it 
impractical to examine specific immune responses. 
  We have examined cytokine secretion by peripheral blood lymphocytes 
(pbl) gathered from a Phase I/II study in hormone refractory prostate 
cancer. Patients were shown to be free of bone metastases and 
immunocompetent on entry. Each individual received a mixture of three 
allogeneic prostate lines plus BCG adjuvant on weeks 0 and 2. Patients 
received cells alone on week 4 and monthly thereafter for one year. 
Blood samples were taken at visit and weekly on weeks 12-16 and 32-
36.
  Pbl were thawed and stimulated overnight with either PHA/ionomycin 
or LPS. Cytokine levels were measured in the supernatants  by 
cytometric bead array (CBA) and the producing cells’ RNA used for 
real-time PCR with absolute quantitation.
 Data from 15 subjects initially showed significant elevations in TH1 
cytokines in patients with marked increases in PSA doubling times. As 
the trial progressed, this phenotype became mixed TH1 and TH2. Patients 
with no PSA response showed either a complete lack of  cytokine 
detection or elevated TH2 cytokines. Interestingly, protein and cDNA  
levels correlated well up to week 16 and then cDNA levels appeared 
depressed compared to protein.
 The major goal of cancer research is the development of therapeutic 
agents specifically aimed at tumour cells. One mechanism potentially 
amenable to chemotherapeutic intervention involves cytochrome P450 
CYP1B1.  Our research has established the concept of over-expression 
of individual forms of P450 in particular CYP1B1 ina range of solid 
tumours.  Moreover our invitro studies have demonstrated the presence 
of metabolically active CYP1B1 and cytochrome P450 reductase in 
tumour samples. We have previously identified several anti-cancer drugs 
(docetaxel, paclitaxel, mitoxantrone and flutamide) as substrates for 
CYP1B1. Furthermore, our in vitro studies have shown that the presence 
of CYP1B1 reduces the efficacy of docetaxel.  In this study we used 
expressed human CYP1B1 in a competitive microassay involving the 
deethylation of ethoxyresorufin to resorufin to extended our screen of 
anti-cancer drugs and identify which ones interact with CYP1B1, by the 
change in resorufin production over time.  Our findings to date indicate 
that a range of structurally diverse anti-cancer drugs interact with 
CYP1B1 (melphalan, bleomycin, methotrexate, altretamine, ellipticine, 
resveratrol, carmustine, dactinomycin, raltitrexed, epirubicin, and 
mitomycin C). Several of these drugs have been further characterised to 
determine their mechanism of interaction with CYP1B1.  The over-
expression of CYP1B1 in tumour cells and interaction of this P450 with 
anti-cancer drugs highlight CYP1B1 as an important P450 in tumour 
cells.
  Acknowledgement: This research was funded by Cancer Research UK 
and the Gray Fund. 
LOW FREQUENCY OF CONSTITUTIONAL WT1  
MUTATIONS IN CHILDREN WITH SPORADIC WILMS 
TUMOUR. Suzanne Little*, Sandra Hanks, Linda King-Underwood,
Liz Rapley, Naz Rahman, Kathy Pritchard-Jones on behalf of the  
UK Children’s Cancer Study Group (UKCCSG).
   Aim: To ascertain the frequency of constitutional WT1 mutations  
in unselected UK patients with sporadic Wilms tumour (WT) and  
investigate heritability.
    Methods: Constitutional DNA from 294 unselected patients with 
sporadic WT treated at 7 UKCCSG centres was screened for 
mutations in WT1 by heteroduplex analysis. 11 samples in which  
>20% of PCR fragments failed were excluded. Suspected mutations 
were confirmed by sequencing and analysed in parental samples to  
investigate inheritance. The cohort included 264 unilateral WT,  18 
bilateral and 1 extrarenal.
  Results: Six children had constitutional WT1  mutations: a 
nonsense and a splice site mutation in exon1, a frameshift in exon3 
and three nonsense mutations in the zinc finger region (R301X and  
two identical R390X mutations), the latter are recognised somatic  
and constitutional mutations in Wilms tumour. These mutations 
were not present in any of the 9 parents tested. The WT1 mutation 
group had a young median age at diagnosis (13.8m), 4 were  female, 
2 were male. Only 1/6 had bilateral tumours, all were  favourable 
histology. Only 1/6 had congenital abnormalities  (ptosis, bilateral 
cryptorchidism). None had family history of  renal disease or early 
onset cancers.
   Conclusions: This study demonstrates that a small proportion  
(2.12%: 95%CI 0.44%-3.80%) of children with apparently sporadic  
Wilms tumour carry constitutional WT1  mutations. Only 2/6 had  
features suggestive of genetic predisposition.  These findings have 
implications for the counselling of patients with Wilms tumour and 
their parents.
    We thank all UKCCSG centres who contributed to this study and  
the families for their participation. 
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MAGNETIC RESONANCE SPECTROSCOPY (MRS) TO
STUDY CHEMOTHERAPY RESPONSE IN A PAEDIATRIC
EMBRYONAL RHABDOMYOSARCOMA (Rd) MODEL. 
Sucheta J Vaidya
*, Yuen-Li Chung, Geoffrey S Payne, 
Martin O Leach,   John R Griffiths, C Ross Pinkerton. 
Royal Marsden NHS Trust, Institute of Cancer Research, Surrey 
and St George’s Hospital Medical School, Tooting, UK. 
  Aims: In vivo 
31P MRS can be used to obtain information non-invasively 
on tumour bioenergetics (NTP/inorganic phosphate (Pi) ratio), intracellular 
pH, and membrane metabolism (measuring phosphorylcholine (PC) and 
phosphorylethanolamine (PE)). The aim of this study was to investigate 
these as surrogate markers for tumour response after ifosfamide (Ifos) 
therapy in Rd xenografts with a view to translating these 
pharmacodynamic markers to clinical studies.
 Methods: Rd xenografts were grown in nude mice.  When tumour size 
reached 582 ± 47 mg, in vivo localised
 31P MRS was performed before and 
7 days after treatment with saline (control, n=5) or Ifos (250mg/kg, n =11). 
Tumours were then extracted and analysed using complementary high 
resolution 
31P MRS in vitro.
Results: At 7 days, tumour volume changed by 7±7% after Ifos compared 
with an increase of 102± 19% after saline (p = 0.006). (PE+PC)/Pi (p = 
0.03) and β-ATP/Pi (p=0.04) ratios were significantly increased in Ifos-
treated tumours, whereas there were no significant changes in controls. PE 
was also increased in the extracts of Ifos-treated tumours compared with 
control (p = 0.005) The in vitro finding confirmed the in vivo data and 
showed that the rise of the (PC+PE)/Pi ratio in vivo was due to increased 
PE, with PC and Pi unchanged.
 Conclusions: Significant changes in tumour bioenergetics and membrane 
metabolism were found after chemotherapy. This suggests measurements 
with 
31P MRS could be used as a useful non-invasive surrogate marker in 
clinical studies.  
THE INCIDENCE OF CANCER IN ADOLESCENTS AND YOUNG
ADULTS IN SOUTH EAST ENGLAND. AN ANALYSIS OF
THAMES CANCER REGISTRY DATA 1998-2000 
Murphy DM
*, Dolbear C, Møller H, Whelan JS, Pinkerton CR
*Department of Paediatrics, The Royal Marsden Hospital, Sutton,
SM2 5PT 
Cancer patients aged 15-24 years have distinct needs. They are
recognised as a special group in The Cancer Plan. High quality cancer
statistics are vital for service planning.  
      Anonymised individual level data for the years 1998-2000 were
obtained from Thames Cancer Registry. For registered cancers in the
age range 10-24 years frequency tables were produced. Tumours were
categorised using the new Birch-Alston (Manchester) classification. A
total of 1,394 tumours were identified over approximately 7.7million
person years at risk. Annual incidence rates per million were
calculated based on mid-year population estimates for the study
region. Age specific incidence rates for each 5-year age group: 10-14,
15-19 and 19-24 years were calculated. Direct standardisation to the
world population was used to calculate an age-standardised rate. A
crude analysis of service requirement was formulated using registry-
derived figures for uptake of chemotherapy, radiotherapy and surgery.
Overall rates in the three age groups were 97.3, 167.8 and 268.2 per
million person years respectively. Lymphoma was the commonest
diagnosis in all age groups. Our results closely mirror nationally
published data. We have described a population of teenagers and
young adults, using a novel classification scheme that helps target
studies in young cancer patients. 
CELL DEATH FOLLOWING EXPOSURE OF ESFT CE  LLS TO 
bFGF IS EFFECTED BY Ap38-DEPENDENT UP-
REGULATION OF DEATH RECEPTORS.
James Boyne* and Susan Burchill.
Cancer Research UK, St James's University Hospital, Leeds. 
The aim of this study was to further characterise the role of death
receptors in bFGF-induced cell death in Ewing’s sarcoma family
tumour (ESFT) cell lines, and examine the hypothesis that
expression of these receptors may be regulated by sustained
activation of the MAPK p38 and/or ERK. The ESFT cell lines
studied differentially expressed the death receptor p75
NTR, 
however, there was no correlation between the level of p75
NTR
expression and induction of cell death by bFGF.  Up-regulation of 
p75
NTR occurred 48h after exposure to bFGF in ESFT cells that
died following exposure to bFGF, but was unchanged in cells that
did not die. To identify whether other apoptotic genes are up-
regulated in response to bFGF, a commercially available apoptotic 
cDNA microarray was probed using total RNA isolated from
bFGF-treated and untreated TC32 cells. Three additional death
receptors were upregulated in bFGF-treated TC-32 cells compared 
to the control: CD95/Fas, DR5/KILLER and the TRAIL decoy
receptor DcR2. To determine if p38 or ERK signalling is required
for up-regulation of death receptors following exposure to bFGF,
TC-32 cells were pre-treated with either SB202190 (p38 inhibitor) 
or PD98059 (ERK inhibitor) and then exposed to bFGF or were left 
untreated. Western analysis demonstrated that both CD95/Fas and
p75
NTR are upregulated post-treatment with bFGF when compared 
to untreated control, and pre-treatment with the p38-inhibitor 
SB202190 prevented upregulation of these two death receptors.
However pre-treatment with the ERK inhibitor PD98059 had no
effect on death receptor expression following exposure to bFGF.
THE MITOCHONDRIAL APOPTOTIC PATHWAY IS
ACTIVATED BY CISPLATIN IN OSTEOSARCOMA. 
1Sally Roberts, 
2Tim Eden and 
1Helen Robson* 
1Departments of
Clinical Research and 
2Paediatric Oncology, Christie Hospital NHS
Trust, Wilmslow Road, Manchester, M20 4BX.   
  Chemotherapy has dramatically improved the prognosis for 
osteosarcoma but a proportion of patients still develop drug 
resistance.  Cisplatin (cDDP) is reported to be the most active agent 
but the mechanisms by which it induces cell death are not clearly 
defined.  Caspases 3 and 9, play an important role in cDDP-induced 
apoptosis in other cell types. Caspase 9 activation occurs following 
release of cytochrome c (Cyt c) from mitochondria.  We investigated 
mitochondrial apoptotic pathway activation by cDDP in the HOS 
cell line.
 HOS cells stained with the mitochondrial membrane potential(∆ϕ) 
sensitive probe JC-1 demonstrated a reduction in within 45 min of 
cDDP (1-10µg/ml) addition.  Cyt c release and pro-caspase 9 and 3 
activation were determined by Western blotting. Low levels of Cyt c 
were found in only the mitochondria of control cells.  In cDDP 
(10µg/ml) treated cells, Cyt c was present in the cytosol and at 
higher levels in the mitochondria after 1 and 0.5 hours respectively.  
Pro-caspase 9 was present in cytosolic extracts of control and cDDP 
treated cells at all time points but was present in the mitochondrial 
fraction of only cDDP treated cells.  These cells showed low levels 
of cleaved active caspase 9, 0.5 hours after treatment, which 
significantly increased by 2 hours.  High levels of caspase 3 were 
present in the cytosol of cDDP treated cells at all time points but was 
virtually undetectable in controls.
  These results show activation of a mitochondrial apoptotic pathway 
by cDDP in human osteosarcoma cells.  Greater understanding of the 
mechanisms involved will assist in efforts to over come resistance.
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1p DELETED NEUROBLASTOMA CELLS DIFFERENTIATE 
FOLLOWING CHROMOSOME 1 REINTRODUCTION
Nidal Boulos
*, Robert F. Newbold, Deborah A. Trott, Andy DJ 
Pearson, Mike J.Tilby, John Lunec 
*Northern Institute for Cancer Research, Newcastle, NE2 4HH,UK
Aims Chromosome 1p deletions and MYCN amplification are common 
genetic abnormalities in neuroblastoma (NB) correlating with a poor 
prognosis.  Deletion and somatic cell fusion studies suggest that multiple, 
and as yet unidentified, tumour suppressor genes on 1p are involved in NB 
development and possibly control MYCN expression. Methods & Results 
This hypothesis was investigated by microcell mediated chromosome 
transfer. Whole human chromosome 1 (Chr1) transfer into IMR-32 cells 
(1p deleted and MYCN amplified) generated 14 hybrids, 5 of which 
exhibit morphological changes including neurite outgrowths. The extent 
of Chr1 incorporated into the hybrids was determined by a panel of 35 
Chr1 microsatellite markers. Hybrids carried material from 1q and 
proximal 1p regions, but none acquired material telomeric to the D1S2890 
marker on 1p32.1.  Immunofluorescence and western blot analysis showed 
increased expression of the neurofilament marker NF-200kD in the 
differentiated hybrids but interestingly, no downregulation of MYCN 
expression.  Subsequent transfer of Chr1 fragment (1p36-1q23) into IMR-
32 cells failed to generate viable hybrids.  To control for procedural 
effects, Chr17 transfer was performed.  Of 26 hybrids, none show altered 
morphology. Unlike Chr1, whole Chr17 is acquired by IMR-32 cells. 
Conclusion The results are consistent with the hypothesis that 
reintroduction of distal 1p (1p36-1p32) is not compatible with growth in 
NB cells having amplified MYCN status.  The marked differentiation seen 
in 5 hybrids and their expression of neuronal markers suggest that other 
regions of Chr1, particularly 1p21.2-1p21.3, can suppress the transformed 
status of NB and induce differentiation without altering MYCN 
expression.
FUNCTIONAL ANALYSIS OF TWO S.pombe GENES
WHICH SHOW A STRUCTURAL SIMILARITY TO THE
LEUKAEMIA ASSOCIATED HUMAN MLLT10 GENE.
Louise K. Jones*
1, Nasser Hajibagheri
2, Vaskar Saha
1, Bryan
D. Young
1 and Takashi Toda.
3 Cancer Research UK Children’s
Cancer Group
1 and Medical Oncology Unit
2, 3
rd Floor, John
Vane Science Building, Barts and The London School of
Medicine and Dentistry, Queen Mary University of London,
Charterhouse Square, London, EC1M 6BQ.   
   Reciprocal chromosomal translocations are associated with acute 
leukaemias. 5-10% of these translocations result in the fusion of the 
MLL on 11q23 to a number of other genes, including MLLT10. 
MLLT10 encodes a 1084aa protein and contains a LAP/PHD zinc 
finger, together with a functional nuclear localisation signal, AT hook 
motif and a leucine zipper.
     Two AF10 “like
,,
 genes have been identified in S. pombe. Deletion 
of both genes PAL1 and PAL2 (pombe AF10 Like)indicates that the 
genes are non-essential in yeast. In addition, Over-expression of human 
MLLT10 is deleterious for fission yeast. Cells in which MLLT10 is 
overproduced are highly elongated, reminiscent of cell cycle delay. 
Nuclear staining with DAPI shows an altered “halo” like chromatin 
structure, and FACS analysis shows abnormal ploidy. Electron 
microscopic analysis demonstrates extensive cytosolic vacuolisation 
and increased numbers of mitochondria and peroxisomes. Immunogold 
labelling of anti-AF10 antibody localises MLLT10 to the nucleus, and 
specifically the condensed chromatin. These results may indicate that 
overproduction of MLLT10 results in the disturbance of pathways 
involved in chromatin DNA structure and vesicle trafficking by 
interacting with endogenous yeast proteins.
THE INTERACTION OF THE ETS TRANSCRIPTION 
FACTOR FAMILY AND ITS CO-REGULATORY 
PROTEIN AIB-1 PLAYS AN IMPORTANT ROLE IN 
HER2/ NEU OVER EXPRESSING BREAST CANCER
Eddie Myers*, Arnold Hill, Yvonne Buggy, Enda Mc 
Dermott, Niall O’Higgins, Leonie Young 
Department of Surgery, St Vincent’s University Hospital 
and the Conway Institute, UCD, Ireland
 HER2/neu over expressing breast cancers have a poorer prognosis. 
Activation of the Ets transcription factors, Ets-1, Ets-2 and PEA3 
are implicated in the transcriptional regulation of HER2/ neu. The 
transcriptional activity of Ets is thought to be modulated by nuclear 
regulatory proteins, including amplified in breast cancer 1 (AIB1).
 Our aims were to localise the transcription factors and AIB-1 in 
breast cancer using immunohistochemistry and to co-localise them 
using immunofluoresence. The ability of the growth factors bFGF 
and EGF to modulate the protein expression of the Ets transcription 
factors in primary breast cultures and breast cancer cell lines was 
assessed using western blotting.
  PEA3, Ets-1, Ets-2 and AIB-1 were localised within breast cancer 
tissue. The transcription factors and AIB-1 were co-localised to the 
same cell. Growth factors induced an up-regulation in the protein 
expression of the Ets transcription factors in a dose dependant 
manner.
The growth factors, bFGF and EGF regulate Ets transcription 
factors.  Co-localisation with AIB1, implicates nuclear regulatory 
protein interaction in the modulation of Ets activity in human breast 
cancer. 
LOW RISK PERSISTENT GESTATIONAL TROPHOBLASTIC
DISEASE TREATED WITH LOW DOSE METHOTREXATE 
Farzana K Khan*, Jan Everard, Samreen Ahmed, Robert E 
Coleman, Muriel Aitken,  Barry W Hancock.  Gestational 
Trophoblastic Disease Centre, Weston Park Hospital, Sheffield 
Between 1987 and 2000, 250 patients were treated with
intramuscular methotrexate 50mg on alternate days (1,3,5,7) with
four doses of oral folinic acid 7.5mg rescue on alternate days
(2,4,.6,8), with 7 days between courses.   
The overall complete response rate without recurrence was 72%
for first line treatment and 95% for those who required second
line chemotherapy.  Eight women (3.2%) had recurrence
following remission and 2(0.8%) had new moles.  Two died of
their disease giving an overall cure rate of 99%.  Only 10 women
(4%) experienced grade 3 or 4 toxicity during the first course of
treatment and 14 women (5.2%) subsequently.  The main
toxicities were mucositis and pleuritic chest pain.  141 women
(56.4%) became pregnant following treatment;  128 (90.7%) of
these were full term normal pregnancies.  No second
malignancies have been observed. 
Methotrexate with folinic acid rescue is an effective treatment for
low risk persistent trophoblastic disease.  It has minimal severe
toxicity, excellent cure rates and does not appear to affect overall
fertility.  Taking the Charing Cross, London [McNeish et al. J
Clin Oncol 2002, 20:1838], and Weston Park, Sheffield, joint
experience for all low risk patients treated in the UK (735 over 14
years) the cure rate approaches 100% - a testament to the
effectiveness of the national surveillance and treatment scheme.
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5 YEAR FOLLOW-UP OF A PHASE 3 TRIAL OF
NEOADJUVANT CHEMOENDOCRINE THERAPY IN
OPERABLE BREAST CANCER Kumar R LAL*, Susan Cleator,
Sue E Ashley, Trevor J Powles. Royal Marsden Hospital, Downs
Road, Sutton,, SM2 5PT, 
 Background We have previously reported a randomized trial of adjuvant versus 
neoadjuvant chemoendocrine therapy for the treatment of patients with primary 
operable breast cancer (1) and shown no difference in overall survival (OS) or relapse 
free survival(RFS). However, those patients in the neoadjuvant arm who responded 
well to treatment had an improved RFS but not a significantly improved OS compared 
to those patients who failed to respond.We now update these results with a further 3 
years of follow-up data. Methods 309 women were randomised to either primary 
surgery followed by 8 cycles of adjuvant mitoxantrone, methotrexate with tamoxifen 
(2MT) with or without mitomycin-C(3MT) or the same chemoendocrine regimen for 4 
cycles before and 4 cycles after surgery. Radiotherapy was prescribed according to 
standard criteria. Tamoxifen was continued for 5 years for estrogen receptor positive 
patients. 142 patients were treated in the adjuvant arm and 144 patients were treated in 
the neoadjuvant arm. Median age was 56 years (27-70). Patient demographics were 
balanced between the two arms. Median follow-up of patients is 111 months (range 10 
months - 131 months). Results There is still no significant difference in OS or RFS 
when comparing women receiving adjuvant versus neoadjuvant treatment. As in 
previous reports the 73 patients in the neoadjuvant arm who achieved a complete or 
near complete response with “minimal residual disease” (CR,MRD) had an improved 
RFS compared with the 69 patients who achieved a partial response or who 
demonstrated no change (PR, NC).The 5 year RFS is 87.3% (77.0 - 93.2%, 95%CI) vs 
71.4% (58.9 - 80.8%) (p =0.03.). Those neoadjuvant patients who achieved a CR or 
MRD now have a statistically significant improved OS compared to the patients 
achieving PR or NR  with 89.2%(79.5 - 94.4%) versus 71.4% (59.3 - 80.5%) (p 
=0.02).  Conclusions 5 years follow up has shown that clinical response to 
neoadjuvant chemotherapy is associated with a statistically significant advantage in 
terms of RFS and OS. To our knowledge this is the first report of an improvement in 
OS for patients demonstrating a good clinical response that is apparent after prolonged 
follow-up. 1 MakrisA, Powles T J, Ashley S Eet al. 1998 Ann Oncol 9: 1179. 
PHASE III STUDY OF VINORELBINE PLUS EPIRUBICIN
VERSUS EPIRUBICIN ALONE IN FIRST-LINE
CHEMOTHERAPY OF METASTATIC BREAST CANCER: AN
SCANDINAVIAN BREAST GROUP STUDY (SBG9403) 
Bent Ejlertsen, Henning T. Mouridsen, Sven T. Langkjer, Jorn
Andersen, Johanna Sjöström, Mogens Kjaer
  The therapeutic benefit of adding vinorelbine to epirubicin was evaluated 
in patients with metastatic breast cancer.
  A total of 387 patients were randomized to receive intravenous 
vinorelbine 25 mg/m² days 1 and 8 plus epirubicin 90 mg/m² day1 (EV) or 
epirubicin 90 mg/m² day1 (E). Both study regimens were given every 3 
weeks until progressive disease, excessive toxicity or a maximum of one 
year. Cumulative dose of epirubicin should not exceed 950 to 1000 mg/m². 
Prior anthracycline-based adjuvant chemotherapy and prior chemotherapy 
for metastatic breast cancer was not allowed. The primary endpoint was 
progression-free survival (PFS).
 The 2 study arms were well balanced for patient and tumour 
characteristics. Median number of cycles (9) and median cumulative doses 
of epirubicin (758 and 729 mg/m²) were similar. Overall response rates 
(RR) to EV and E were 50% and42%, respectively. The complete RR was 
significantly higher in the combination arm (17% versus 10%, p =0.048). 
Median PFS was significantly longer with EV compared to E (10.1 versus 
8.2 months, p = 0.019). Addition of vinorelbine to epirubicin reduced the 
risk of progression by 25% (p= 0.006). Median survival was 19.1 months 
with the combination and 18 months with epirubicin alone (p = 0.50). 
Leucopenia-related complications, stomatitis and peripheral neuropathy 
were more frequent with the combination. Incidences of cardio-toxicity, 
constipation and injection site reactions were not significantly different 
between the two arms.
  In conclusion, addition of vinorelbine toepirubicin conferred a significant 
advantage in terms of complete response rate and progression-free survival. 
VITAMIN D IN BREAST CANCER 
Kathryn McCarthy*, Christiana A Laban, Sarah E Bonner, Ragheed Al 
Mufti,  Stephen A Bustin, William Ogunkolade, P J Jenkins and R 
Carpenter. 
Depts of Breast Surgery, Barts and The London, Queen Mary School 
of Medicine and Dentistry.
  Background: Previous studies have shown an association between vitamin D 
deficiency and breast cancer risk. Vitamin D is also known to inhibit the mitogenic 
and anti-apoptotic effects of IGF-1 in breast cancer cells; the bioavailability of IGF-
1 is regulated by insulin-like growth factor binding protein-3(IGFBP-3). The local 
expression of vitamin D in the breast, however, is unknown. Furthermore, it 
remains to be determined whether these effects involve IGFBP-3.
  Aims: i)To quantify the expression of 25-hydroxyvitamin D-1-alpha-hydroxylase 
(1 alpha OHase), the enzyme which converts 25 hydroxyvitamin D to its active 
metabolite, in paired normal and malignant breast tissue and to correlate this 
expression with that of IGFBP-3 mRNA and tumour phenotype(histology, 
oestrogen receptor (ER) status, vascular invasion and lymph node metastases).
  Methods:  Total RNA was extracted from 21 paired samples of normal and 
malignant breast tissue. Local Ethical Committee Approval was obtained. mRNA 
transcription was quantified using a real time, hydrolysis probe-dependant RT-PCR 
assay (‘Taqman’).
  Results: 1α-OHase and IGFBP-3 mRNA were expressed in all samples. 1α-
OHase was significantly down regulated in normal compared to malignant breast 
tissue (median copy no 2.27x10
7 vs 5.62x107, p=0.01). Furthermore, a positive 
correlation was found between 1 α-OHase and IGFBP-3 mRNA expression in the 
tumours (R=0.61, CI 0.24-0.824, p=0.005). There was no difference in tumour size, 
grade and ER status between tumours with high and low 1 α-OHase expression (+/-
5.00x10
7).
 Conclusions: The significant down regulation of 1 α-OHase in normal compared 
to malignant breast tissue supports a role for vitamin D in early breast 
tumourigenesis. The significant correlation in tumours between 1 α-hydroxylase 
and IGFBP-3 expression supports the view that IGFBP-3 might influence the 
regulatory effects of vitamin D in breast cancer.  
CORRELATION BETWEEN BCL-2 EXPRESSION AND
DIFFERENT CLINICO-PATHOLOGICAL VARIABLES IN
HUMAN BREAST CANCER 
Alaa T Abdel-Rahman*, E Husain, C Wells, and R Carpenter. St
Bartholomew’s Hospital, Breast and Endocrine Unit, London.
  Introduction Bcl-2 plays an important role as an inhibitor of 
apoptosis that may extend the viability of cells containing genetic 
alterations and facilitate tumour progression. Inspite of this anti-
apoptotic effect, Bcl-2 expression is associated with good prognosis in 
breast cancer. The aim of this study was to relate Bcl-2 expression to 
differing clinico-pathological variables in breast cancer.
  Methods We reviewed fifty-four patients with breast cancer. 
Immuno-histochemical methods were used together with modified 
quick score of archival paraffin-embedded sections of tumour.  Bcl-2, 
HER-2/neu, oestrogen receptor, androgen receptor and progesterone 
receptor were assessed. Expression of Bcl-2 was also related with age, 
menopausal status, lymph node status, tumour size, tumour grade and 
tumour types.
   Results Age range was 29-84 years (mean 59.4Ys). Bcl-2 expression 
was significantly correlated with increased age >50 years (P-value 
<0.001), tumour grade I (P-value <0.01), and tumour size  <20mm(P-
value<0.05). No statistical relations between Bcl-2 expression and 
menopausal status, lymph node status, tumour types, HER-2/neu 
expression, oestrogen receptor status, androgen receptor status or 
progesterone receptor status were found.
 Conclusion We confirm that Bcl-2 is related to favourable 
pathological variables. Its assessment in combination with these 
variables might allow selection of patients with good prognosis who 
might avoid aggressive systemic therapy.
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DIFFERENTIAL REGULATION OF BREAST CANCER CELL 
PROLIFERATION BY DIETARY PHYTOESTROGENS. Jane 
Limer
*, Sarah Burdall, Andrew Hanby, Sally Lane & Valerie 
Speirs. Molecular Medicine Unit, Clinical Sciences Building, 
University of Leeds, Beckett Street, LS9 7TF.
The incidence of hormone dependent cancers is lower in Asia as 
compared to Western nations. The Asian diet is traditionally high in 
phytoestrogens (PEs), which exhibit putative anti-cancer activities.This 
research aims to determine the growth effects of the dietary PEs 
daidzein, genistein and coumestrol in human breast cancer cells, also 
investigating potential mechanisms of ER-mediated signalling.
 The characterisation of ER expression using flow cytometry revealed 
ER as the predominant receptor subtype in MCF-7 cells, whilst equal 
levels of ERα  and ERβ protein were detected in T47-D. Both ER-
positive cell lines demonstrated biphasic growth responses following 
0.1-50µM PE treatment, as determined by proliferation assays and cell 
cycle analysis. Physiological doses of 0.1-10µM genistein and 
coumestrol stimulated MCF-7 and T47-D growth and S-phase activity, 
whilst concentrations in excess of 25µM induced G2/M phase arrest. A 
dose-dependent stimulatory effect of daidzein was observed in MCF-7, 
however T47-D growth was inhibited only at 25µM. Reporter gene 
assays suggest the involvement of ER-dependent signalling via the 
activation of ERE and AP-1 response elements.
    We have additionally assessed the effects of PEs on novel primary 
breast epithelial cultures established from tumour tissue. Tumour cell 
proliferation was similarly stimulated by PE doses of 0.1-10µM. Our 
data therefore suggests that the ingestion of dietary PEs may exacerbate 
the growth of ER-positive breast tumours. Thismay be a cause for 
concern for post-menopausal subjects using PEs as a natural alternative 
to HRT. 
FACTORS PREDICTING AXILLARY LYMPH NODE
INVOLVEMENT IN PATIENTS WITH SMALL BREAST
CANCERS 
*Sankha.S.Mitra ,Sue Ashley, Aseem.Y.Rostom
Correspondence address: 41 Alexandra Avenue,Sutton,Surrey SM1 
2PA
We carried out a retrospective analysis of patients with tumours <10mm seen 
at the Royal Marsden Hospital between 1990 and 2002 from our perspective 
database. All patients had axillary node dissection and we have full 
histological information on lymphovascular invasion, ER/PR status, number 
of involved nodes and the tumour grade. Patients who received neoadjuvant 
chemo/endocrine therapy or preoperative irradiation were excluded.
  Results: 452 patients met the analysis criteria.
 Discussion: Ninety-eight out of the 452 patients (21.7%)with tumours under 
10mm had axillary lymph node involvement.  Even in grade I tumours, there 
is a 12.8% incidence of nodal involvement. With holding axillary sampling 
in these patients may result in understaging of a significant number of 
patients.
 We found vascular invasion and grade of the tumour to be independent 
predictors for nodal involvement. 58% of the node +ve patients had vascular 
invasion while only 41%of the node +ve patients had no vascular invasion. 
The incidence of nodal involvement increased with grade, being 12.8% for 
grade I tumoursand 29% for grade III tumours. Higher grade tumours tended 
to have a higher incidence of vascular invasion.
  We found that 56% of the node +ve patients were ER +ve while only 
15.3% of node +ve patients were ER-ve. This is thought to reflect the higher 
frequency of ER +ve patients (276/452) skewing the data as 19.9% of ER 
+ve patients were node +ve compared with 26.7% of ER-ve patients. 
Therefore, a higher percentage of ER-ve patients seem to have nodal 
involvement.
 Conclusion: Vascular invasion, grade and ER –ve status are all predictive 
factors for lymphnode metastasis. 
TWELVE WEEKS OF NEOADJUVANT CAPECITABINE (CAP) 
AND OXALIPLATIN (OX) FOLLOWED BY SYNCHRONOUS 
CHEMORADIATION (CRT) AND TOTAL MESORECTAL 
EXCISION (TME) IN MRI DEFINED POOR RISK LOCALLY
ADVANCED RECTAL CANCER RESULTED IN PROMISING 
TUMOUR REGRESSION AND RAPID SYMPTOMATIC RELIEF
Ian Chau
*, David Cunningham, Diana Tait, Gina Brown, Niall 
Tebbutt, Mark Hill, Andrew Wotherspoon, Andrew Norman, Alison
Massey
*Department of Medicine, Royal Marsden Hospital, Downs
Road, Sutton, Surrey SM2 5PT 
Purpose: To evaluate neoadjuvant cap/ox prior to CRT and TME in newly 
diagnosed patients (pts) with MRI defined poor risk/locally advanced rectal 
cancer.  Methods: Pts received 12 weeks of neoadjuvant cap 
(2000mg/m
2/day po for 14 days every 3 weeks) and ox (130mg/m2 iv every 
3 weeks). Starting on week 13, cap was continued at 1650mg/m2/day 
continuously with concomitant radiotherapy. TME was planned 6 weeks 
after CRT. Post-operatively, pts received 12 weeks of cap at 2500mg/m
2/day. 
MRI was repeated after chemotherapy and CRT. Results: Between 
November 01 and November 02, 22 eligible pts were recruited. Median age 
was 62 (range=38-80). So far, 17 patients are evaluable for radiological 
response and 15 patients have proceeded to TME. Following neoadjuvant 
cap/ox, all pts had partial responses (RECIST criteria). In addition, 80% of 
pts had symptomatic responses in a median of 22 days (i.e. after one cycle 
of chemotherapy) including reduced rectal bleeding (100%), improvement 
in diarrhoea/constipation (79%), diminished pelvic pain/tenesmus (64%) 
and weight gain/stabilisation (100%). Following CRT, tumour response was 
sustained in all pts. Of 20 pts with initial threatened circumferential 
resection margin (CRM), tumour regression away from the CRM occurred 
in all pts who have completed treatment so far allowing R0 resection in 
100% of these pts. Pathological CR was found in 5 pts. Conclusion: 
Capecitabine and oxaliplatin prior to synchronous CRT and TME produces 
almost universal tumour regression, rapid symptomatic response and allows 
R0 resection to be achieved. 
LATE EFFECTS FOLLOWING TOTAL MESORECTAL
EXCISION AND SHORT COURSE PREOPERATIVE 
RADIOTHERAPY 
Margaret King
1* Shaun Tolan
1, Selveraj Giridharan 
1, Chris 
McConkey
2, Andrew Hartley
1, Ian Geh
1 
1Cancer Centre, Queen Elizabeth Hospital, Birmingham B15 2TH
2Cancer Research UK Clinical Trials Unit, University of  
Birmingham
   Introduction Late side-effects following short course
preoperative radiotherapy (SCPRT) and total mesorectal excision
(TME) for operable rectal cancer have not been adequately studied.
Acute toxicity in a series of 176 consecutive patients has been
previously reported. In this study, late effects in the same cohort
are presented. 
Method Side effects occurring more than 3 months after the start
of SCPRT were graded using the EORTC/RTOG late radiation
toxicity system. Multivariate analysis was performed to identify
associated factors
   Results Of 176 patients, 15 died within three months of SCPRT
and 5 patients were lost to follow up. At a median follow up of 40
months severe (grade 3-4) toxicity was seen in 20 (13%) of 156
assessable patients: Gastrointestinal 13 (8%); Other 7 (5%). On
multivariate analysis, abdominoperineal (AP) resection (p<0.001)
was associated with less severe toxicity. 
   Conclusions In this retrospective series the rate of late grade 3-4
toxicity following SCPRT and TME was 13%. Although AP
resection is associated with a lower incidence of late side-effects
this may be counterbalanced by the impact of a stoma on quality of
life. These factors should be considered when deciding on the
optimal management of operable rectal cancers. 
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CHEMORADIATION IN LOCALLY ADVANCED RECTAL 
CANCER USING BOLUS 5-FLUOROURACIL, Suzannah 
Mawdsley*
1  & Rob Glynne-Jones.  
1The Gray Cancer Institute,
Mount Vernon Hospital, Northwood, Middlesex HA6 2RN, UK. 
  Introduction: Chemoradiation prior to surgery is now a common 
approach in the treatment of locally advanced rectal cancer. This
report describes the resection, survival and local relapse rates of 
patients treated over an 8-year period at Mount Vernon Hospital.  
Methods: Between 1994 and 2002, 155 patients with a locally
advanced adenocarcinoma of the rectum were treated. T stages
were: T2:2, T3:59, T4:94.  Median age 67 years, male: female ratio 
73:27%. The radiotherapy dose was 45Gy in 25 fractions over 5 
weeks. 5-FU was given as a 60 minutes infusion on days 1-5 and 
29-33, at 350mg/m2, following low dose folinic acid. Surgery was 
performed in 114 patients. Actuarial survival, local control and 
toxicity rates according to CTC criteria, were assessed. 
Results: 93% of patients achieved 100% compliance during 
chemoradiation, common toxicities were diarrhoea, tenesmus and 
skin reactions. Resected specimens revealed 12% had a 
complete pathological response (CPR), downstaging occurred in 
41%, in 37% there was no change and 10% were unresectable. R0 
resections were achieved in 95/155 (61%). Overall median survival 
was 37 months with a 5-year survival of 34%. Median time to local 
recurrence (LR) was 22 months and occurred in 8% of R0 and 11% 
of R1/2 resections. 54/155 (35%) cases developed distant 
metastases in a median time of 19 months.
Conclusion: Chemoradiation with 5-FU can produce effective 
downstaging in patients with locally advanced rectal carcinoma 
and toxicity is manageable. Survival appears poor in this group and 
the results of the Phase III EORTC trial with 5FU/folinic acid are 
awaited. Phase two studies are in progress to investigate the use of 
newer agents in combination with 5FU, which may not only
improve LR and R0 resection rates but also impact upon survival. 
LYMPH NODE STAGING FOLLOWING PREOPERATIVE 
CHEMORADIATION IN RECTAL CANCER. Mark Beresford*, 
Robert Glynne-Jones, Andreas Makris, Mark Harrison. Mount 
Vernon Cancer Centre, Northwood, Middlesex HA6 2RN. 
   Introduction: The lymph node (LN) status of rectal cancers is a 
key prognostic indicator. UICC guidance suggests that at least 12 
LNs should be examined before a tumour can be pronounced node-
negative. Others suggest that 7 or 8 LNs might be sufficient, but 
with increasing usage of neoadjuvant chemoradiation (NCRT) the 
effacement of LNs means that often far fewer are found.  
   Patients and methods: 185 patients with T3 or T4 rectal cancer 
treated with NCRT between 1994 and 2002 have been entered into 
a prospective database. All patients were deemed inoperable on 
initial staging. Treatment was with concurrent radiotherapy (45 Gy
in 25 fractions over 5 weeks) and leucovorin/5FU chemotherapy. 
   Results:  134 males and 51 females had a mean age of 63. A 
total of 161 patients (pts) proceeded to surgery. The mean number 
of LNs found in the resection specimens was 5.47 (range 0-21). 
Complete pathological response was seen in 19 pts (12%). Overall 
3-year survival figures were 54%. For node positive pts this fell to 
43%, with a disease free survival (DFS) of 16%. In node negative 
pts with 2 or less nodes examined, 3-year survival figures were 
47% (DFS = 26%). Where 3 or more negative nodes were found, 
overall survival was 66% (DFS = 58%). 
   Conclusions: LN status following chemoradiation is predictive 
of survival. There is considerable effacement of LNs, resulting in a 
yield lower than would be traditionally required for prognostic 
information. We demonstrate that if more than 2 negative nodes 
are found, the outcome is more favourable than if 2 or less 
negative nodes are identified. It seems likely that this is due to 
understaging of pts in whom insufficient nodes are recovered, and 
we suggest that following NCRT at least 3 nodes are required 
before a specimen can be considered truly N0. 
THE MRC CLASICC TRIAL: RESULTS OF SHORT-TERM 
ENDPOINTS 
Pierre J. Guillou*, Phil Quirke, Nick Bosanquet, Adrian Smith, 
Helen Thorpe, Joanne Walker, Sue E. Bell, Julia M. Brown.
Northern & Yorkshire Clinical Trials & Research Unit, University
of Leeds, UK. 
This large prospective, multicentre, multidisciplinary, pragmatic, 
phase III trial was designed to compare conventional (Open) 
versus laparoscopic-assisted (Lap) surgery in colorectal cancer in 
terms of pathological, clinical and health economic outcomes. 
Patients were randomised in an unbalanced allocation of 2:1 Lap: 
Open resection. Recruitment closed on 31 July 2002 with a total of 
794 patients (526 Lap, 268 Open). 
   Primary short-term endpoints  were pathological  resection 
margins and 30-day operative mortality. Secondary short-term
endpoints were blood transfusion requirements, operative 
complication rates and short-term quality of life. All pathological 
data were centrally reviewed. Longer-term endpoints are defined 
as recurrence and metastases, disease-free and overall survival.  
Pre-treatment characteristics: 413 colon, 381 rectal, median age 
70 years, 56% male, 87% WHO performance status 0-1. Data 
were analysed in an intention-to-treat analysis. Circumferential 
margin positivity rate was 13% (Open) and 15% (Lap), p=0.68; 
longitudinal margin rate was 0% (Open) and 1% (Lap), p=0.31; 
30-day operative mortality was 4% in both arms, p=0.82; 30-day
complication rate was 36% in both arms, p=0.97. Pathological 
data were excellent with lymph node median yield of 13 overall. 
This trial provides an early indication of the role of laparoscopic 
resection in colorectal cancer. The short-term results suggest that, 
in the UK, the laparoscopic-assisted technique for colorectal 
cancer appears to be no different from open surgery. It is the only
trial considering rectal cancer, and is unique in its high-quality
pathological data collection and pathological endpoints. 
THE DEVELOPMENT OF α  -FOLATE RECEPTOR (α-FR) 
TARGETED THYMIDYLATE SYNTHASE (TS) INHIBITORS 
Ann L. Jackman*, David Gibbs, Davinder Theti, Matthew Green, 
Florence Raynaud, Melanie Valenti, Vassilios Bavetsias. Haddow 
Laboratories, Institute of Cancer Research, Sutton, Surrey.
The targeting of anticancer drugs to tumours seeks to exploit a 
difference in the biology of tumours compared with that of normal
tissues. One such difference is the high expression of the α-FR in 
some epithelial tumours e.g. 90% of ovarian. The α-FR, linked to 
increased susceptibility to malignant transformation and regulation 
of tumour proliferation, also is a high affinity, low capacity
transporter of folates. The reduced-folate carrier (RFC) is the 
primary folate/antifolate transporter and its ubiquitous expression 
leads to antifolate cytotoxic effects in tumours and normal tissues. 
TS inhibitors such as raltitrexed, pemetrexed and ZD9331 are also 
co-transported via the α   -FR in some preclinical models. Thus, we 
hypothesised that a TS inhibitor displaying high and low affinity
or the α   -FR and RFC respectively could be an α-FR-targeted 
drug. Two cyclopenta[g]quinazoline-based compounds, CB300638 
and CB300945, possess this profile (TS Ki = 0.24nM and 1.4nM 
respectively). Following rapid binding to the α  -FR they are slowly
trafficked via an endosomal pathway. The 72h IC50 in A431-FBP 
(α-FR transfected) and KB (α  -FR constitutive) cells is ~3nM 
while in α   -FR negative lines is ~1 to 10µM. Both compounds 
localised to the KB xenograft in mice (100mg/kg i.p. bolus) 
compared to normal tissues. Target inhibition in tumour, but not in 
normal tissues, was demonstrated using 
125IdUrd metabolism as a 
surrogate marker of TS inhibition. By contrast, selective targeting 
in this model was not seen with ZD9331. CB300638 and 
CB300945 have been selected as potential drug candidates that are 
predicted to display efficacy in α  -FR
+ tumours and very low 
toxicity. Supported by Cancer Research UK.      
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RANDOMISED, MULTICENTER PHASE III STUDY 
COMPARING CAPECITABINE WITH FLUOROURACIL AND 
OXALIPLATIN WITH CISPLATIN IN PATIENTS WITH 
ADVANCED OESOPHAGOGASTRIC CANCER: 
CONFIRMATION OF DOSE ESCALATION.
Catherine Harper-Wynne*, Kate Sumpter, David Cunningham
Andrew Norman, Jaqui Oates, Claire Durrant,Tim Iveson, 
Marianne Nicholson, Tamas Hickish, Mark Hill,.*Royal Marsden 
Hospital, Downs Rd, Sutton Surrey SM2 5PT. 
PURPOSE: To establish the potential use of the third generation
platinum compound, oxaliplatin (O) & the oral fluoropyrimidine
capecitabine (X) in untreated patients (pts) with advanced
oeophagogastric cancer, using a multicenter randomised study.
METHODS: Pts were randomised to 1 of the 4 regimens;
epirubicin, cisplatin, fluorouracil (ECF), EOF, ECX or EOX.
Doses: E 50mg/m
2, C 60mg/m
2 & O 130mg/m
2 IV 3 weekly; F
200mg/m
2/day IV & X 1000mg/m
2/day (escalated to
1250mg/m
2/day) PO, continuously. The first interim analysis was 
performed after 80 pts had been randomised. 5.1% of X treated pts 
experienced grade 3/4 toxicity of the dose limiting
fluoropyrimidine toxicities; stomatitis, palmar plantar erythema
(PPE) and diarrhoea. A protocol dose escalation to 1250mg/m
2
was therefore instituted and a 2
nd interim analysis has been 
performed. 
RESULTS: 204 pts have been randomised. From 176 pts evaluable 
for toxicity 10.7% of the 1250mg/m
2 capecitabine group 
experienced non-haematological grade 3/4 toxicity. From 153 pts 
evaluable for response, combined CR + PR rates for each regimen 
are: ECF 31%, EOF 33%, ECX 35% and EOX 52%.  
CONCLUSIONS: The non-haematological toxicity of 10.7% in the 
1250mg/m
2 capecitabine group confirmed this as the optimal dose, 
which will therefore be used until the planned total accrual of 600 
patients. Updated data will be presented at the meeting. 
PATIENT’S EXPERIENCES OF LUNG CANCER DIAGNOSIS 
Meinir Krishnasamy & Erna D Wilkie* 
Correspondence Address: Erna D Wilkie. Research Nurse, 
Department of Cancer Medicine, Ninewells Hospital & Medical 
School, Dundee, DD1 9SY, Scotland.
This paper draws on data drawn from two studies undertaken to 
assess the health care needs of patients with primary lung cancer. In 
the first of the two studies (a national mail questionnaire survey), 
209 (45%) patients accessed from 24 randomly selected hospitals
throughout the UK, returned completed questionnaires. Participants
responded to questions relating to their experiences of care 
provision from time of first presenting to their GP, on through 
treatment and into follow-up. The second of the two studies, draws 
on in-depth interview data gathered from a cohort of 60 patients 
with lung cancer who agreed to take part in interviews at one, three 
and six months post diagnosis.  
Although the considerable impact of the diagnostic process and of 
its “telling” on cancer patients’ construction of their experience of
care are well documented, little is known of the process and 
associated outcomes of the diagnostic pathway for patients with 
lung cancer. Given that the median survival for patients with lung
cancer after diagnosis is less than four months, with about 80% of 
patients dying within one year
1, the need to ensure that the 
diagnostic process is swift, well co-ordinated and therapeutic in its 
own right, is imperative.  
Data from our studies suggest that work needs to be undertaken, 
and its effect evaluated, to better inform the public of symptoms
that warrant urgent attention. 
THE USE OF MVP CHEMOTHERAPY IN MALIGNANT
MESOTHELIOMA: OUTCOME AND PREDICTIVE FACTORS 
E Andreopoulou*, PJ Ross, MER O’Brien, A Norton, K Priest, S Ashley, 
S Popat, C Harper-Wynne, K Sumpter, IE Smith. Lung Unit, Royal 
Marsden Hospital, Downs Road, Sutton, Surrey, SM2 5PT. 
This study aimed to assess the palliative benefit of MVP chemotherapy
in patients (pts) with mesothelioma and assess prognostic factors. Pts
with histologically confirmed mesothelioma were treated with
mitomycin-C 8mg/m
2 (courses 1,2,4 &6), vinblastine 6mg/m
2 (maximum
10mg) and cisplatin 50mg/m
2 IV q 21 days for up to 6 cycles. 150 pts 
were treated and analysed for objective and symptomatic tumour
response, toxicity and survival. The overall response rate was 15.3% 
(95% CI 9.3–21.4%) and 68.6% demonstrated no objective change. 147
pts reported symptoms at the start of chemotherapy and 69% had a
symptomatic response to MVP, including 2 pts with a complete
resolution of all symptoms. There were no toxic deaths. The most
frequent grade 3/4 non-haematological toxicities were infection (12%),
nausea/vomiting (9%) and constipation (5%). Grade 3/4 haematological
toxicities were neutropaenia (22%), anaemia (6%) and
thrombocytopaenia (5%). Median survival was 7 months and at 1-year
31.6% (95% CI:24.0–39.5%) were alive. Univariate analyses
demonstrated that poor performance status (WHO 2/3) (p=0.003), weight 
loss (p=0.009), non-epithelioid histology (p=0.003), low haemoglobin
(<13 g/dl in males and <11.5g/dl in females) (p=0.008), low white cell
count (<11x10
9/l) (p=0.008) and low absolute neutrophil count (<5.0 x 
10
9/l)(p=0.02) were all significant prognostic factors. Multivariate
analysis demonstrated that weight loss (relative risk [RR] 3.34,p=0.001), 
non-epithelioid histology (RR 2.69,p=0.01), low haemoglobin (RR 2.41,
p=0.01), low white cell count (RR 2.94,p=0.001) were all independent
prognostic factors. 
We conclude that MVP is a palliative regimen which can be given safely
even to pts with poor performance status. In addition, we have confirmed 
that weight loss, non-epithelioid pathology, and anaemia are poor 
prognostic factors. To improve outcomes treatment strategies will need to 
address symptoms such as weight loss and anaemia.
Dr E Andreopoulou was supported by an ESMO Fellowship 
LOCAL IMMUNE RESPONSE IN ANAL HPV RELATED LESIONS. 
COMPARISON BETWEEN HIV POSITIVE AND HIV NEGATIVE
POPULATIONS 
*J. Mullerat
1, F. Deroide
2, B. Lloveras
3, W. Quint
4, M. C. Winslet
1, M. 
Bofill
5
University Department of 
1Surgery,
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Royal Free and University College Medical School, London, U.K, 
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Laboratory, Institut Catala d’Oncologia, L’Hospitalet, Barcelona, Spain, 
and 
4Delft Diagnostic Laboratory, The Netherlands. 
Most cases of anal carcinoma develop from high grade anal intraepithe-
lial neoplasia (AIN) caused by persistent human papillomavirus (HPV) 
infection. We studied the host’s local cellular immune response in HPV-
related anal lesions and compared the results between HIV + and HIV - 
groups.   This study assessed the degree of local T lymphocytic infiltrate 
(CD-3, CD-4 and CD-8) in the stroma and epithelium of HPV related 
anal lesions in 75 patients (41 HIV – and 34 HIV+) with immunohisto-
chemistry, and the HPV serotype/s by PCR detection of carcinogenic 
HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68).
There was a local lymphocytic infiltrate in the stroma and epithelium,
in all groups of lesions. The T cell infiltrate (CD4 and CD8) showed a 
significant (p<0.05) increase as the lesions became gradually dysplastic 
and invasive both in HIV – and HIV + groups. The cell infiltrate was 
significantly lower in the HIV + group for each group of lesions, mostly
at the expense of CD4 cells. 74% of lesions in the HIV – group and 88% 
in the HIV + group contained carcinogenic HPV types. This difference 
was not statistically significant.
This is the first study that shows a local cellular immune response in 
anal HPV lesions. These data also suggest that the poorer prognosis in 
HIV + patients is likely to be due to their inherent cellular immunosu-
pression, rather than a higher exposure to carcinogenic HPV types. 
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CHART TO CHARTWEL TO CHEMOTHERAPY AND 
CHARTWEL IN NON-SMALL CELL LUNG CANCER 
B E Lyn*, E M Wilson, F J Williams, M I Saunders, H Phillips 
Mount Vernon Cancer Centre, Mount Vernon Hospital, 
Northwood, Middlesex, HA6 2RN, UK 
The CHART trial showed a 9% improvement in survival, 29% 
compared with 20%, in patients with locally advanced inoperable 
non-small cell lung cancer treated with CHART compared with 
conventional daily radiotherapy to 60Gy. As centres found 
treatment on week ends difficult, the CHARTWEL, CHART Week 
End Less, protocol was developed and in a feasibility study the 
dose was gradually increased to 60Gy in 17 1/3 days. Three 
courses of neo-adjuvant chemotherapy were then added prior to 
CHARTWEL. Initially, chemotherapy was with the MIC 
(Mitomycin, Ifosfamide and Cisplatin) regime but later PC 
(Paclitaxel and Carboplatin) was used. Other regimes included 
MVP (Mitomycin, Vinblastine and Cisplatin) and VC (Vinorelbine 
and Cisplatin). 
The 2 year survival was 40% in 20 patients treated to <60Gy, 
47% in 55 patients treated to 60Gy and 47% in 33 patients treated 
with chemotherapy and radiotherapy. The addition of 
chemotherapy led to increased dysphagia but reactions settled in 
all cases. Twenty four percent of those receiving chemotherapy 
and radiotherapy suffered grade 2 or worse lung morbidity, higher 
than those treated with radiotherapy alone, but there was no 
significant difference between the schedules. There were no cases 
of myelopathy. 
Induction chemotherapy followed by CHARTWEL to 60Gy is 
feasible and there may be a therapeutic benefit.
ADDITION OF SRL172 TO STANDARD CHEMOTHERAPY IN 
SMALL CELL LUNG CANCER (SCLC) CONFERS NO SURVIVAL 
BENEFIT: RESULTS OF A RANDOMISED MULTICENTRE STUDY 
K. Sumpter*, C.L. Harper-Wynne, M.E.R. O’Brien, P. Johnson, R.Bass, 
T. Goldie, A. Norton, P. Ross, H. Ford. Royal Marsden Hospital, Downs 
Rd, Sutton; Kent Cancer Centre & CRUK Oncology Unit, Southampton. 
Background: SRL172 is a suspension of heat killed Mycobacterium 
vaccae, found to be a potent immunological adjuvant when used with 
autologous cells in vivo. A previous phase II study in SCLC revealed a 
trend to improved median survival with the combination of chemotherapy
and SRL172 and no increased toxicity irrespective of drug regimen used 
[Assersohn et al 2001]. We report a randomised multicentre study
assessing the efficacy and safety of standard chemotherapy with or 
without SRL172 in SCLC. 
Methods: Patients had histologically confirmed limited or extensive 
SCLC and WHO performance status  ≤ 2. Patients could receive either an 
anthracycline or platinum based regimen with randomisation to receive 
intradermal SRL172 at day 0 prior to chemotherapy and weeks 4,8,12, 
and 16. On completion of chemotherapy SRL172 was continued every 8-
12 weeks and on progression SRL172 was continued if further treatment 
of any kind was considered. All patients were followed for survival. 
 Results: 76 patients were randomised and 72 received carboplatin and 
etoposide chemotherapy. There was no difference in response rates 
between the two arms, 73% without vaccine and 68% with vaccine. 
Median duration of response and median survival was 9 months for both 
groups. The standard arm (chemotherapy only) response rate and survival 
was better than the pilot study. 
Conclusion: Despite encouraging phase II results, this study suggests no 
advantage to response or survival in adding SRL172 to standard 
treatment in SCLC. Improved results in the standard arm of this phase III 
study compared to the anthracycline/low dose platinum regimen used in 
the phase II study may account for the lack of difference. Putting together 
this result with SRL172 in SCLC and the results of SRL172 in NSCLC, 
the strategy of combining SRL172 with chemotherapy will not be 
pursued. This study was supported by SR Pharma.   
SMALL CELL LUNG CANCER: CAN PROGNOSTIC 
MODELS HELP US IN THE CLINIC?
Ewan Brown
*, Melanie Mackean 
Edinburgh Cancer Centre, Crewe Road South, Edinburgh, UK. 
  Background:  Prognostic models have been extensively
studied in small cell lung cancer. The 'prognostic tree model'
(Sagman et al. J Clin Oncol 9:1639-1649,1991) divides patients
into four distinct groups according to routinely collected clinical
and laboratory data. This retrospective review aims to assess
whether this model divides patients into therapeutically
important groups when applied to a cohort of patients with
small cell lung cancer in South-East Scotland.  
  Methods: Between 1999-2000, 162 patients with small cell
lung cancer were identified through the cancer registry at the
Edinburgh Cancer Centre and variables including age,
performance status, extent of disease and laboratory parameters
(including LDH, WCC and AlkPhos) were assessed and
survival for each prognostic group was calculated. 
  Results: Patients had a median age of 67 (range 38-88). 69
patients had limited disease (43%). Median survival was 89
days for extensive disease patients and 415 days for limited
disease. When divided into prognostic groups according to the
'tree model' the median survivals for the 4 groups were 484 days
for group A, 293 days for group B, 120 days for group C and
46.5 days for Group D respectively.
  Conclusion:  The 'tree model' divides patients into 4 easily
definable groups when applied to this cohort of patients. Use of
the model provides useful prognostic information and may help
in the clinic in targeting patients for specific treatments. In
particular it may be useful in selecting patients within the
limited or extensive disease groups who may benefit from more
aggressive therapy and those who will not. 
DETECTION OF RARE DISSEMINATED TUMOUR CELLS 
IDENTIFIES HEAD AND NECK CANCER PATIENTS AT
RISK OF TREATMENT FAILURE 
Max Partridge*, Ruud Brakenhoff, Elaine Phillips, Kulsan Ali, 
Rebecca Francis Richard Hooper, Kenneth Lavery, Andrew Brown, 
John Langdon. Correspondence address Maxillofacial
Unit/Oncology, King's College Hospital, London, SE5 8RX, UK.
In this study, samples of bone marrow (BM) and venous blood 
collected preoperatively and three months post-surgery for 40 head 
and neck cancer patients, were screened for the presence of
disseminated tumour cells (DTCs)  using immuncytochemistry
(ICC) with a pan cytokeratin antibody and E48 RT-PCR to 
establish the most appropriate samples and assay to incorporate 
into prospective studies.  The molecular approach was also applied
to intraoperative central venous blood (CVB). the concordance 
between the molecular and ICC tests applied to preoperative 
samples, measured by Cohen’s kappa, was not uniformly good
(BM 0.62, CVB 0.12), likely reflecting sampling errors, 
heterogeneity of E48 antigen expression or stochastic effects. 
However, testing samples of BM and CVB preoperatively with the 
molecular or ICC approaches gave results that predicted disease 
free survival (DFS) and distant- metastases free survival (DMFS). 
Application of a single preoperative test predicted development of
distant metastases but there was also evidence that the prediction
could be improved by combining information derived from testing
both CVB and BM.  Testing the intraoperative sample of CVB was 
also a sensitive predictor of distant metastases, but testing BM or
peripheral venous blood three months post-surgery was not useful. 
The discordance between the results obtained with the
postoperative E48 RT-PCR and ICC may reflect the presence of
epithelial cell debris in the haematopoietic cell compartment (HCC) 
after radiotherapy. These findings suggest that detection of DTCs 
pre- or intraoperatively signals for a high risk of local and distant 
recurrence and reduced survival in head and neck cancer. 
≤
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OUTPATIENT CHEMO-RADIOTHERAPY FOR LOCALLY
ADVANCED HEAD AND NECK CANCER USING  WEEKLY
CISPLATIN  Gwo F Ho*, Caroline H Bridgewater, Melanie EB 
Powell, Dept of Radiotherapy,
St. Bartholomew’s Hospital, London EC1A 7BE
Aim:  To determine the feasibility and toxicity of a cisplatin 
based outpatient chemo-radiation regimen in locally advanced 
squamous cell carcinoma (SCC) of the head and neck.   
Methods:  Patients with locally advanced head and neck cancer, 
performance status 2 and GFR 50ml/min were considered for 
radical chemo-radiation.  Radiotherapy (66Gy in 33 daily
fractions) was given with concurrent weekly outpatient cisplatin 
(40mg/m
2)  and acute toxicity assessed weekly.  Initial clinical 
response was evaluated at 3 months post treatment.   
Results:  Since May 2000, twenty patients have received this
schedule. A mean number of 4.7 chemotherapy cycles were given 
(range 2-6) and the median duration of radiotherapy was 44.5 days
(range 37-47). All patients completed radiotherapy as planned.
Six patients required a total of 9 hospital admissions for treatment 
related toxicity.  Causes were nausea/vomiting (4), neutropaenic 
sepsis (2), constipation (2) and mucositis (1).  Eight patients 
required blood transfusion and 2 had asymptomatic grade 3 
neutropenia.  One developed total dysphagia.  Skin and mucosal 
reactions were not unduly severe, and had healed in all patients by
12 weeks, one has subsequently developed radiation necrosis. 
With a median follow up of 5 months (range 1-19), there have 
been 16 complete responses, 2 partial responses, and 2 patients 
with progressive disease.  Two patents have died with local 
recurrence.   
Conclusion:  Chemoradiotherapy with weekly outpatient 
cisplatin is a well tolerated and feasible treatment for advanced 
head and neck SCC.  Response is encouraging but long term
results are awaited.
INFORMATION NEEDS OF ASIAN AND WHITE ENGLISH
CANCER PATIENTS AND THEIR FAMILIES IN 
LEICESTERSHIRE: A CROSS SECTIONAL SURVEY  
R Paul Symonds
*, D Muthu Kumar, Santhanam Sundar, Kausher 
Ibrahim, Boki SP Savelyich, Ed Miller Department of Oncology
and University of Leicester, Leicester Royal Infirmary Leicester 
LE1 5WW
The aim of the study was to find the information needs of 
British Asian cancer patients.  An additional objective was to 
find the extent of family involvement when the patient was given 
the cancer diagnosis and the patient’s views about information 
disclosure.  82 Asian patients and 220 random white English 
control patients visiting the Leicestershire cancer centre were 
included in a questionnaire survey.  This is the first survey of the 
information needs of an ethnic minority group with cancer.   
More white English patients gave positive answers to the 
statement “I want as much information as possible” than Asian 
patients (93.1% v 77.5% p =<0.001).  However, 92.6% of Asian 
patients wanted to know if they had cancer.  Many more Asians 
(66.2% v 51 % p < 0.001) indicated their GP was the preferred
source of information.  The vast majority of both Asian and 
English patients agreed that family or friends should be present 
when patients are given the cancer diagnosis.  However, Asians 
were more likely to be alone 24% v 15% (p = < 0.008) when told 
they had cancer.  The majority of patients (both white English 
and Asian) want to control the disclosure of information to 
relatives and friends and would like to be present at
doctor/family meetings.  We suggest all patients attending an 
appointment where they will be told bad news should be invited 
to bring friends or family members.  Further research is needed 
to find how to increase the role of the GP in giving diagnostic
and prognostic information to Asian patients.
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